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(iii)
SUMMARY
In order to develop new compounds for the rapid and effective
diagnosis of melanoma in vivo, a number of radioisotopically labelled
quinoline derivatives were prepared and tested in experimental animals.
131
Because of the intrinsic necessity to introduce

I into the molecule

at the latest possible state of the synthesis, the labelled compounds
were prepared mainly through the Sandmeyer reaction.
During the course of this work twenty new quinoline derivatives
and two new acrylate intermediates were synthesised.

In addition

three monoiodoquinolines and two 4-amino-X-iodoquinolines labelled with
131
I together with five tritioquinolines were prepared for the first
time.

The yields of several of the reported preparative procedures

were also greatly improved.
The structural factors influencing the uptake of the labelled
quinoline derivatives by melanomas and other pigmented tissues were
elucidated from the distribution of the radioactive label in the
various tissues of the experimental animals.

In this way, it was

established that :
(i)

Monoiodoquinolines had no selective affinity for pigmented
tissue

(ii)

4-Aminoquinoline had no selective affinity for pigmented
tissue

(iii)

4-Amino-X-iodoquinoline derivatives had a highly selective
affinity for pigmented tissue

(iv)

In respect of the affinity for pigmented tissue 6-iodo-4aminoquincline and 7-iodo-4-aminoquinoline were equivalent

(v)

About eight times as much radioactivity from 4-amino-6-iodoquinoline and 4-amino-7-iodoquinoline concentrated in
melanomas by parenteral administration than if given orally

(vi)

By contrast; higher concentrations of labelled 4-(3-dimethylaminopropylamino)-7-iodoquinoline were found in melanomas
when given orally than by intraperitoneal injection.
123

The possible use of
is discussed.

I as an alternative in melanoma diagnosis
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INTRODUCTION

MELANOMA AND ITS DETECTION
In tropical and subtropical climates where the population is
exposed to high intensity solar radiation for much of the year the
incidence of skin cancer in fair skinned people of white races is
considerably higher than in the more temperate regions of the Earth. ^
A causal relationship has been established between the degree of ultra
violet irradiation of the skin and the incidence of melanoma, a tumour
of the melanocytes, i.e. of the cells in which pigment is produced in
the body.

2

Although this is a comparatively rare condition in non

white races (even in albinos) there has been a progressive increase
2

throughout the world in the mortality attributed to this cause.

In

Australia, where there are long hours of strong sunlight and a
predominantly white population of Anglo-Saxon origin, the death rate
from melanoma is the highest in the world and it has been observed to
2

increase with proximity to the Equator.

Where a substantial

proportion of the population is employed in outdoor activities, such
as in the pastoral industries in Queensland, the death rate is
particularly high but the mortality does not reflect the exceptionally
2

high incidence of the tumour
State. ^

or of skin cancer in general in this

Because there is a great public awareness of the danger of

malignant skin conditions patients usually seek prompt medical attention
so that melanoma can be diagnosed and treated at an early stage when
cures can be readily effected.
It is comparatively easy to diagnose melanoma as it is readily
accessible in the skin.

However incisional biopsy of skin lesions

is rigorously avoided since the surgical procedure m i g h t result in
3
the dissemination of m a l i g n a n t cells throughout the b o d y .

Once

m e t a s t a t i c m e l a n o m a occurs deep w i t h i n the body and the lesions cannot
be detected by radiography or p a l p a t i o n , it is desirable to define the
extent and the spread of the disease w i t h o u t surgical exploration.
One such method for the detection and location of malignant lesions
relies on the binding of a compound labelled w i t h a radioactive nuclide
to the m a l i g n a n t cells or to a component thereof.

If sufficient of

the labelled compound is concentrated in the melanoma to differentiate
it from the surrounding tissue, and provided the decay of the radioactive nuclide is accompanied by the emission of gamma r a d i a t i o n , then
the tumour can be detected from outside the b o d y .
Since the success and limitations of this technique to detect
internal tumours depend on the measurement of the distribution of
radioactivity w i t h i n the body it is fortunate that considerable
technical advances have been made w i t h i n recent years in the developm e n t of equipment for this p u r p o s e .

A number of instruments are

available commercially, among them the gamma camera which can provide
an oscilloscope display of the distribution of radioactivity detected
by a large area scintillation crystal and data can be recorded for
subsequent computer analysis to assist evaluation of the visual display.
The quality of the display and therefore the reliability of the
diagnosis depends on sufficient radiation reaching the scintillation
crystal for recognition of the difference between a lesion and the
background radiation from the surrounding tissue.

If a tumour is
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BIOSYNTHESIS OF M E L A N I N A N D

EPINEPHRINE.

small or does not concentrate the radioactive compound well enough
then it can be overlooked.

This is less likely to occur when a

rectilinear scanner is used since this instrument is more suitable
than the gamma camera for the measurement of low levels of radio4
activity.

In this case the intensity of radiation detected by a

scintillation counter is recorded either in analogue form on chart
or photographically as a series of profiles across the body at small
incremental distances.

In addition to these relatively sophisticated

instruments useful information can be obtained by a simple counting
procedure over areas of the body with a gamma scintillation counter.
This method has some advantages since counting in a small area can be
carried out over a long enough time period to obtain statistically
significant results.

The areas of the body to be measured in this

way can be selected on the basis of their known propensity to be
sites of metastases.
Melanin Precursors
Initially the use of a precursor of melanin labelled with a
radioactive nuclide had been proposed since biosynthesis to melanin
in the body (Fig.l^) accompanied by its concentration in pigmented
tissue would enable detection of melanomas with the help of the
14
6
equipment described above. However with
C labelled tyrosine (1)
3
14
and either

H or

C labelled dopa (dl-3,4-dihydroxyphenylalanine)

the radioactivity was incorporated not only into pigmented
tissue but also into the adrenals.

Although these compounds were

known to be also precursors of epinephrine (3) which is found in the

adrenals it had been hoped that the distribution of the labelled
compounds between the two biosynthetic routes would be in favour of
the production of radioactive melanin.

In fact the experiments

showed that almost equal amounts of radioactivity were concentrated
in both melanoma and adrenals and higher concentrations were found
only in rapidly growing, deeply pigmented tumours.
3
Despite the difficulty of detecting concentrations of

14

H or

G

in melanomas from outside the body (since they emit only soft beta
radiation) the absorption of this soft beta radiation within a very
small depth of tissue enables these nuclides to destroy the cells
in which the labelled compounds are concentrated.

Tritium labelled

compounds are particularly suitable for this purpose as the radiation
14
damage is limited to the immediately surrounding tissue whereas

C

labelled compounds can incorporate, by some unforseen reaction, into
other tissues and damage healthy tissue.

This hazard is considerably

less with tritium labelled compounds because this nuclide is excreted
relatively rapidly from the body and therefore would be less likely to
excessively irradiate other tissues.

Unfortunately much of the

tritium in labelled dopa proved to be labile.

Any possible use of

this compound to attack melanoma was abandoned as it was thought that
insufficient radioactivity would be concentrated in the tumour to bring
about therapy.^

Furthermore it was estimated that the quantity of

H labelled compound for radiotherapy would result in the excessive
irradiation of some organs e.g. the gut.
Two attempts have been made to prepare melanin precursors

labelled with a nuclide emitting gamma radiation for use in the
detection of melanoma.

By taking advantage of the ability of dopa

to form chelates with metal ions, its
in tumour bearing mice.

8

51

Cr chromium chelate was tested

Although the distribution of

51
Cr differed

14
from that of

C labelled dopa the highest concentrations were found

in the adrenals and in the melanoma.

A major drawback with this

material is the emission
of gamma radiation from only 87o of the
51
disintegrations of

Cr.

Consequently a greater quantity of this

nuclide is required to enable detection to be made from outside the
body.

The absence of further reports in the literature suggests

that the unfavourable nuclear properties of ^^Cr have led to the
discontinued use of this chelate.
To overcome the problem of labelled melanin precursors giving
rise to both melanin and epinephrine, compounds9 closer to the final
stage of melanogenesis were tested in animals.
One such compound,
the gamma emitting 5,6-dihydroxy-7-iodoindoletoo unstable in air to permit testing.

131

I, proved to be

While 5,6-diacetoxy-7-

131
iodoindole-

I was sufficiently stable, it displayed no selective

concentration in pigmented tissue.

It was thought that this result

might be due to the introduction of the iodo group and consequent
impairment of the subsequent biological transformation of this melanin
precursor.

When a similar lack of specificity was found for 5,6-

diacetoxyindole-2-^^C, the failure of the

labelled compound to

concentrate in pigmented tissue could not be attributed to the
presence of an iodo group.

Attempts to introduce radioactivity
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QUINOLINE AND THE DERIVATIVES CONCENTRATED IN
PIGMENTED TISSUE,

into melanotic tissue by means of labelled melanin precursors have
been discontinued since some derivatives of quinoline (4, Fig.2.)
not known as precursors were found to concentrate in melanin
containing tissue by a mechanism as yet unexplained.
Quinoline Derivatives
(a)

In Diagnosis

The search for a melanoma selective radioactive compound led to
the antimalarial drug, 4-(4-diethylamino-l-methylbutylamino)-7chloroquinoline (5) known as chloroquine.^^

The affinity of this

compound for melanin was first recognised by its deposition in the
pigmented tissues of the eye to such an extent that prolonged
administration of this drug has been known to result in retinopathy^^
i.e. pathological changes in the retina with impairment of vision.
Concentration of chloroquine by the pigmented eye tissues is
remarkably specific and it has been shown to accumulate in the foetal
eye in animals.

12

Incorporation into eye tissues occurs rapidly,

within 48 hours of administration, with preferential storage in the
13
iris and the choroid.

Once taken up by these tissues chloroquine

is released only over a long period.
Although chloroquine shows a number of useful pharmacological
properties e.g. as an anti-inflammatory agent in the treatment of
rheumatoid arthritis

its antimalarial activity is superior to all

other compounds tested in the antimalaria programme conducted by the 14
U.S. Office of Scientific Research and Development from 1941 to 1945.
The corresponding iodo compound, 4-(4-diethylamino-l-methylbutylamino)-

7-iodoquinoline (6), named iodoquine and 4-(3-dimethyla^linopropylamino)-7-iodoquinoline (7) which differs from iodoquine only in the
nature of the side chain, have less antimalarial potency ^^ but,
also bind to melanin.^^'^^

When each of the above iodo compounds

125
labelled with either

131
I or

I were tested, preferential

concentration of the radioactivity was found in the pigmented
tissue.

Melanomas in animals

were located by

scanning

^nd melanotic tumours in humans

when they could not be detected radio-

graphically or by palpation.^^'^^

In contrast radioiodine in the

form of sodium iodide showed no preferential concentration in pigmented

10,20
tissue.
On subsequent evaluation of the use of the labelled quinoline
derivatives in the detection of melanomas within the body by means
of the radioactivity concentrated in them, the results showed
good
18
correlation with the clinical conditions of the patients.

Because

the affinity displayed by the radioiodine labelled compounds for
melanotic tissue depends on the intensity of pigmentation i.e. on the
melanin concentration, results of limited value only were obtained
from poorly pigmented tumours which did not concentrate
18 sufficient
radioactivity to permit their unambiguous detection.

This situation

occurs in the amelanotic melanomas where malignant cells have almost
entirely lost the ability to produce melanin.

Poor uptake of radio-

activity were also observed in tumours where there was extensive
necrosis and thus contained fewer functioning cells.

In addition

it has been estimated that very small lesions (less than 0.7 cm

diameter) could escape detection on account of the very small amount
of radioactivity associated with them.

21

A useful diagnostic application of the labelled quinoline
derivatives grew out of an investigation of a case of intraocular
19
melanoma.

In this condition there is a primary melanotic tumour

within the eye and which is therefore not accessible for histopathological examination.

Although the practice is to enucleate the

eye whenever this particular form of melanoma is believed to exist,
this operation turns out to have been unnecessary in 197o of the
22

cases.

A technique was evolved whereby radioiodine labelled iodo-

quine or 4-(3-dimethylaminopropylamino)-7-iodoquinoline is administered
to patients with suspected intraocular melanoma and measurements of
the radioactivity are made over each eye for a number of days.

If

a consistently higher value is found in the affected eye this evidence
is accepted as confirming the diagnosis of melanoma.

After examination

of a number of cases in this 22
way it was claimed that the diagnosis can
be made with 957» confidence.

This is a relatively new method for the

diagnosis of intraocular melanoma and so far its potential has not been
adequately assessed.
(b) the
In 125
Radiotherapy
Both
I and the 131 I labelled quinolines have been evaluated
131
for the diagnosis of melanomas but only
I was found suitable for
the destruction of melanotic tumours by the radioactivity concentrated
23
in them in the form of labelled quinoline derivatives.
of the nuclide relevant to this purpose are:-

The properties

(i), the emission of beta radiation to kill the cells to which
the radiation penetrates and
(ii), a half life of 8 days allowing delivery of the radiation
dose before much of the labelled compound is released from pigmented
tissue.

A small daily excretion has been observed to occur although

the labelled quinolines appear firmly bound to melanin.
The use of

131

with some problems.

I labelled compounds in therapy is often associated
In this case loss of the radioactive label by
131

metabolism or isotopic exchange can provide a source of
may concentrate in the thyroid and injure this gland.

I which
In addition

the labelled quinoline derivatives would be concentrated to some
extent in normal pigmented tissues as well as in melanomas.

The

limitations of this treatment therefore depend on the extent to
which the functions of specialised tissues adjacent
to pigmented
131
tissue are damaged by the radiation from the
I taken up by the
pigmented tissue e.g.damage to the retina from

131
I in pigmented eye tissue

131
To assess the potential of

I labelled iodoquine and analogous

compounds in the treatment of melanoma, therapeutic doses of 50 mCi
or more of 4-(3-dimethylaminopropylamino)-7-iodoquinoline were
23
administered to dogs suffering from melanoma.

It had been estimated

that sufficient radioactivity would be concentrated in the tumour to
destroy the malignant tissue.

Although two dogs died before any effect

of radiation on the tumour could be seen, the remaining dog survived
to the end of the experimental period and on examination of this
animal encouraging results were obtained.

The metastatic lesions

had completely regressed and, significantly, radiation damage of the
eyes was absent not only in these dogs but also in a control group
of non tumour bearing dogs which had received similar quantities of
the radioactive compound.

Histopathological examination of the eyes

up to 8 months after the treatment revealed no evidence of damage or
abnormality.
(c)

Structure-Activity

Relationships

No mechanism has yet been established to explain the affinity of
the 4-aminoquinoline derivatives for melanotic tissue but attempts
have been reported in the literature to relate affinity to the
position and nature of some substituent groups.

The significance of

the position of the iodo group in the 4-aminoquinoline derivatives
to the preferential uptake by pigmented tissue has been examined in
animals by comparison between the radioactivity incorporated into
pigmented tissue from radioiodine labelled 4-(3-dimethylaminopropylamino)-6-iodoquinoline and the 7-iodo derivative.

24

While no

significant differences were found between the 6 and 7 substituted
derivatives, there were inconsistencies in the uptake of the 7-iodo
24
derivative.

The high dose rate of compound and different

experimental conditions employed for the tests suggest that this
conclusion should be treated with caution.
It

has also been concluded that a basic group in the 4-position
25

is necessary
examined.

although only a limited number of groups have been

A preferential uptake was found for 7-iodoquinoline

substituted in the 4 position with the 4-methylpentylamino group or

the 3-dimethylaminopropoxy group but this was less than with the
3-dimethylaminopropylamino group.

In contrast, all specificity for

pigmented tissue was lost with a hydroxy group in the 4 position.
Other Compounds
The binding of some phenothiazine derivatives, e.g. chlorpromazine
(2-chloro-lO-dimethylaminopropylphenothiazine) to melanin was
demonstrated at about the same time as the similar property of
26
chloroquine.

However the development of a radioactive phenothiazine

derivative for use in melanoma detection failed to eventuate due to
difficulty in introducing a suitable radioactive nuclide.

Meanwhile

the successful application of radioiodine labelled quinoline derivatives
for this purpose had been achieved^^ and consequently work on
phenothiazine derivatives was discontinued.
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P R E P A R A T I O N O F 4 - A M I N O Q U I N O L I N E S BY

CYCLODEHYDRATION

OF A ß - A N I L I N O A C R Y L A M I D E .

PREPARATION OF 4-AMINOQUINCLINE DERIVATIVES

Methods of Synthesis
Since both of the radioiodine compounds with which melanoma has
been detected previously are 4-aminoquinoline derivatives, the methods
by which 4-aminoquinoline and its derivatives can be prepared are
important to this project.

Once their exceptional antimalarial

potency had been recognised many 4-aminoquinoline derivatives were
tested for antimalarial activity and a consequence of this work was
the development of a number of general methods for the preparation
of those quinoline derivatives.

The starting material common to

many synthetic routes was the same aniline derivative as can be seen
from the principal methods described below

:
27

(a)

Cyclodehydration of a p-Anilinoacrylamide (Fig.3a)
p-anilinoacrylamides

(11), prepared by the reaction of an

aniline derivative (8) with ethyl orthoformate (9) and the amide
of an acid possessing an active methylene group (10) cyclise with
phosphorus pentoxide to yield 4-aminoquinoline derivatives (12) with
a substituent in the 3 position.

A side chain on the 4-amino group

is derived from the substituent on the original amide (10).

When

this reaction was carried out with 3-chloroaniline cyclisation of
the p - 3 - c h l o r a n i l i n a c r y l a t e

formed could lead to either the 5 - c h l o r o

or the 7-chloro derivative.

In fact only the 7-chloro derivative

was found however it has not been established whether the 7
substituted quinoline derivative is the predominant isomer formed

CH,OH

I

C H O H
N H
CHjOH

(16)

FIG.3b.

(14)

(13)

(8)

(17)

(18)

PREPARATION OF 4-CHLOROQUINOLINE THROUGH THE SKRAUP

REACTION.

from other m e t a substituted a n i l i n e s .

This synthesis has the

advantage of leading directly to a 4-aminoquinoline but requires a
substituent to activate the methylene group in the amide (10) w h i c h
leads to an unwanted substituent in position 3 of the q u i n o l i n e .
(b)

P r e p a r a t i o n of 4-Chloroquinoline Derivatives via the Skraup
Reaction
The preparative m e t h o d s below do not result directly in a

4 - a m i n o q u i n o l i n e derivative but they lead to the corresponding
4 - c h l o r o q u i n o l i n e intermediate in w h i c h the chloro group can be
replaced by the desired amino g r o u p .

Quinoline derivatives

(14)

can be prepared from aniline and its derivatives (8) by the Skraup
r e a c t i o n , i.e. by reaction w i t h glycerol (13) in sulphuric acid and
an oxidising agent e . g . arsenic a c i d .

The positions of substituents

in the benzene ring of the quinoline derivative (14) are controlled
by the substitution of the aniline derivative (8).

Thus an ortho

group and a para group lead to the 8 substituted and the 6 substituted
28
quinoline derivatives respectively

while a mixture of the

substituted quinolines is obtained from meta substituted

5 and 7

anilines.

The relative proportions of the isomers
29 30have been shown to depend on
the nature of the substituent group
'
e . g . meta directing groups
give mainly 5 and some 7 substituted quinolines and the reverse
29
applies for o r t h o , para directing groups.
Once the required quinoline derivative has been prepared it can
be oxidised to the N-oxide (15)

•31

'

'

33 3 ^
'
from which a mixture of

COOC2H5

I

C \O O C o H s
CH2

CH2

NHj

- I

CCOOCjHs

C O

COOC2H5

(21)

(20)

(8)

COOC2H5

C O O H

FIG.3c.

(23)

(22)

(24)

(16)

P R E P A R A T I O N O F 4 - C H L O R O Q U I N O L I N E S BY T H E C O N R A D L I M P A C H

SYNTHESIS.

the 2-chloro (17), the 3-chloro (18) and the 4-chloroquinoline
derivative (16) is produced on treatment with a strong chlorinating
31 32
agent, e.g. sulphury1 chloride.

'

Since separation of the

isomers of the chloroquinoline derivatives presents problems an
alternative route for the exclusive preparation of the 4-chloroquinoline derivative (16) from the N-oxide derivative (15) has been
described. 35

This approach relies on the preparation of the 4-

nitroquinoline-l-oxLde derivative (19) by selective nitration of
o 36
the N-oxide (15) which takes place in the 4 position above 40
but at lower temperatures also in the 5 and 8 positions; 37

the only

exception is the nitration of 6-nitroquinoline in the 4 position which
38 39
takes place at room temperature.

'

In the subsequent reaction to

obtain the 4-chloroquinoline derivative (16) treatment of the 4-nitroquinoline-l-oxide derivative (19) with phosphorus trichloride results
not only in the reduction of the N-oxide function but
40 also in the
displacement of the nitro group by a chloro group.
41 42
(c)

Conrad Limpach Synthesis (Fig.3c)

'

After condensation of an aniline derivative (8) with ethyl
ethoxalylacetate (20) the anilinosuccinic ester (21) formed can be
cyclised to produce the 2-carbethoxy-4-hydroxyquinoline derivative
41
(22).

Hydrolysis of this ester to the carboxylic acid (23) followed

by decarboxylation results in the formation of the 4-hydroxyquinoline
derivative (24) which can be converted to the 4-chloroquinoline
derivative (16) in the usual way.

However both the 5 and 7 sub-

stituted quinoline derivatives are obtained from meta substituted
anilines by this synthesis.

COOC^Hs
\ c O O C 2 H 5

II

(26)

COOC,H
2^15

COOH

FIG.3d

(28)

(27)

(24)

(16)

PREPARATION OF 4-CHLOROQUINOLINES BY THE
MALONATE METHOD.

DXETHYLETHOXYMETHYLENE

(d)

Ethoxymethy1enemaIonic Ester Method (Fig.3d)
This synthesis has many points of similarity to the Conrad

Limpach method described above as an aniline derivative (8) is
condensed with diethyl ethoxymethy1enemalonate (25) and the aerylate
formed (26) is cyclised to give the 3-carbethoxy-4-hydroxyquinoline
43
derivative (27).

The essential difference between the methods

stems from the fact that meta substituted anilines result in the
almost complete formation of the 7 substituted quinoline derivative,
instead of a mixture of the 5 and 7 substituted isomers.

This feature

is of particular value since this is the route employed in the
preparation of the 7-halogenoquinoline derivatives which comprise a
large proportion of the materials tested for affinity for pigmented
tissue.

The synthesis is completed by hydrolysis of the 3-carbe-

thoxy-4-hydroxyquinoline derivatives (27) to the carboxylic acid (28)
which is decarboxylated and the resulting 4-hydroxyquinoline derivative
(24) converted to the

4-chloroquinoline derivative (16) in the usual

way.
(e)

Conversion of 4-Chloro to 4-Aminoquinoline Derivatives
Derivatives of 4-chloroquinoline are known to reach with either

ammonia 41 '44 '45 (to produce the corresponding derivatives of 4aminoquinoline), or with a primary amine when a side chain is required
42
on the 4-amino

group.

The actual conditions under which the

reaction will take place depend on the positions of the substituent
groups in the quinoline ring and, in general, it has been found that
milder conditions are required when they occupy positions in the

benzene ring than if they are in the 2 or 3 positions of the hetero
ring.

46

On the other hand secondary amines are reluctant to react

with 4-chloroquinoline derivatives under similar conditions.
it has been established that replacement of a chloro group

47

Since

by an

42
amino group occurs in the 4 position but not in the 5,
6, 7 or 8
positions 46 then the 4,X-dihalogenoquinolines give only the 4-aminoX-halogenoquinoline derivatives;

replacement of the second halogeno

group takes place only under severe conditions of temperature and
pressure.

45

Labelling with Radioiodine
25
In previous work,

radioiodine was introduced into all the

quinoline derivatives tested for uptake in pigmented tissue by
homogenous isotopic exchange i.e. when a radioactive iodine atom
exchanges for a non radioactive one.

In the 7-iodoquinoline deriva-

tives exchange was found to occur only slowly at room temperature but
was brought about more rapidly on heating.

The exchange between

the iodoquinoline derivative and radioiodine supplied as sodium iodide
was ultimately carried out in a high boiling solvent, ethylene glycol,
at about 170°.
4-(3-Dimethylaminopropylamino)-7-iodoquinoline can
24
be labelled in this way and specific activities of 3 mCi per rr^
18

to about 100 mCi per rrM

have been reported.

In contrast this

method was unsuccessful for 4-(3-dimethylaminopropoxy)-7-iodoquinoline
and 4-(4-methylpentoxy)-7-iodoquinoline due to decomposition of the
compounds.

Isotopic exchange took place only in 3-dimethylamino-

1-propanol and 4-methyl-l-pentanol solutions respectively, i.e. in

the alcohol which in each case corresponds to the

4 position side

chain.
There are a variety of routes besides isotopic exchange by means
of which iodine can be introduced into organic molecules.

The

principal methods employed fall into the categories listed below :
48
(a)

addition across a double bond

e.g. the preparation

of 1,2 diiodoethane from ethylene,
(b)

reaction of an alcohol
49with either hydriodic acid or
phosphorus and iodine

e.g. the preparation of ethyl iodide

from ethanol,
(c)

direct iodination with molecular iodine^^, e.g. the
preparation of 3-iodotyrosine from tyrosine.

It should

be noted that a maximum of only half the iodine can be
incorporated into the labelled compound by this reaction,
(d)

iodination with iodine chloride^^ e.g. the preparation of
4,5-diiodofluorescein from fluorescein,

(e)

replacement of a primary aromatic amine through the
52
Sandmeyer reaction

(f)

e.g. the preparation of iodobenzene

from aniline,
mercuration with mercuric chloride followed by replacement
53
with iodide

e.g. the preparation of (4-chloro-2-iodo

phenoxy) acetic

acid from (4-chloro-2-(chloromercuri

phenoxy)acetic acid,
(g)

heterogenous isotopic exchange where 54
radioiodine exchanges
with another halogen in the molecule
e.g. the preparation

of iodoacetic acid from chloracetic acid.
The advantage in methods (a) and (g) above is due to the specific
activity of the labelled product corresponding to that of the radio
iodine used in the labelling.

The same control over the specific

activity of the radioactive material obtained by isotopic exchange
cannot be

exercised because it depends on the extent to which

radioactive atoms have exchanged with non radioactive ones.

Some

success in the preparation of labelled quinoline derivatives by isotopic
exchange had been achieved and, since this approach relies on
established procedures to prepare the non-radioactive compounds e.g.
by the Skraup reaction, the only limitation would arise from failure
to prepare the compound to be labelled.

On the other hand hetero-

genous exchange has not been reported in the literature for the
preparation

of iodoquinoline derivatives but replacement of an
29

amino group through the Sandmeyer reaction has been carried out

e.g.

the preparation of 5-chloro and 5-bromoquinoline (although not for the
preparation of radioiodine labelled compounds).

There is no

restriction on the accessibility of quinoline ring positions by this
method since there are standard methods available to prepare all
aminoquinolines.

The potential value of the
55 Sandmeyer for the

present investigation lay in its reported use

for the conversion

of 4,6-diaminoquinoline to 4-amino-6-halogenoquinoline, from which
it is evident that the 4-amino group in this diaminoquinoline resists
diazotisation.

The other methods of labelling cannot be applied to

prepare quinoline derivatives labelled in any desired position since

the iodination procedures with either molecular iodine or iodine
c h l o r i d e , which depend on electrophilic substitution, are limited
to the susceptible p o s i t i o n s , e . g . 3-iodo-4-hydroxyquinoline

from

4-hydroxyquinoline and 5-iodo-8-hydroxyquinoline from 8-hydroxyquinoline by treatment w i t h iodine chloride.^^

AIMS AND APPROACH

Although the selective concentration in melanotic tissue of
some 4-amino-X-iodoquinoline derivatives has been described^^ and
25
some features of the selectivity have been examined more closely
most attention has been given to the clinical applications of the
labelled compounds.

For a better understanding of the structural

requirements to be met in quinoline derivatives to obtain selectivity
a number of questions remain to be answered, namely :
(i)

Is a substituent group and especially a basic group
necessary in the 4 position for selective uptake by
melanotic tissue?

(ii)

What is the difference in uptake between a compound with
a primary amino group and a compound with a secondary
amino group in the 4 position?

(iii)

Is the selective uptake of 4-amino-X-iodoquinoline by
melanotic tissue affected by having the iodo group in the
5 or 6 positions instead of in the 7 position?

(iv)

Does the degree of selectivity depend on the amount of
labelled compound administered?

(v)

Is the presence of a halogen substituent in the quinoline
ring necessary for the selective uptake by melanotic
tissue?

The aim of this project was to answer the above questions.

To

achieve this purpose it was intended to prepare quinoline derivatives

labelled with

I in the 5, 6 and 7 positions respectively and to

measure the radioactivity in tissues and organs following administration to experimental animals.

Therefore methods were devised to

synthesise these compounds through their respective primary amine
derivatives and to introduce the required amount of radioiodine as
a final step by a micro Sandmeyer reaction.

In the case of the

4,X-diaminoquinoline derivatives it was intended to rely (with
subsequent confirmation of this approach) on the reluctance of the
4-amino group to undergo diazotisation.^^
Where the quinoline derivatives contained no halogen similar
measurements were planned employing the tritium labelled quinoline
derivatives prepared by decomposition of a hydrazino
active protons had been exchanged: with tritium.

group when the

Several known routes

leading to the preparation of amino and hydrazino quinoline derivatives
were compared and, in the course of this work, a number of compounds
not previously described in the literature were prepared.

RESULTS AND

DISCUSSION

A.

PREPARATION OF QUINOLINE DERIVATIVES
In order to prepare the required quinoline derivatives into
131

which

I could be introduced by the Sandmeyer reaction the

synthetic programme commenced with the preparation of primary
aminoquinoline derivatives.
(i)

Monoaminoquinoline Derivatives

Monoaminoquinoline are conveniently prepared by reduction of
the respective nitroquinolines which are usually obtained by standard
methods.

By the Skraup reaction 6-nitroquinoline was prepared from

4-nitroaniline and 5-nitroquinoline from 3-nitroaniline when 7-nitroquinoline was produced as a by-product.

The yield 29
of 7-nitroquinoline

from this preparation was less than the reported one

but was in

agreement with the different ratio of 5-nitroquinoline:7-nitroquinoline (5:1) found in the present work.

The alternative method

of preparing 5-nitroquinoline i.e. by nitration of quinoline, also
results in a mixture of isomers (8-nitroquinoline is the by-product^^).
However the latter reaction was preferred because it took place more
rapidly and more cleanly thatn the former method so the product was
easier to isolate although the yield was not significantly greater.
A number of methods are available for the subsequent reduction
58
of the nitro to the amino group e.g. iron with chloride ions
or
acetic acid,

59,60,61

^
, T . , 60,61,62,63,64,65 , ,
stannous chloride,
hydrazine

with Raney nickel,^^ hydrogen with Raney

nickel,palladium

catalyst in acid,^^ and alcoholic solution^^ or Adams catalyst.^^

In early experiments 5-nitroquinoline was reduced with iron powder
and 6-nitroquinoline with either stannous chloride or iron and acetic
acid in low hields

(617o,

567o

and

667o

respectively).

In all cases

the low yields were attributed to difficulty in recovering the aminoquinolines from the reaction mixture containing high concentrations
of metal ions.

Subsequently catalytic hydrogénation was found

to give the most facile reductions of the nitroquinolines in high
yields (about

907o)

and with the advantage that the progress of the

reaction was indicated by the consumption of h y d r o g e n .

By reductions

carried out in this way 5,6 and 7-aminoquinolines were readily obtained
in high purity but since they are susceptible to decomposition in
air and sunlight refrigerated storage in sealed containers was
necessary to m a i n t a i n the purity.
the adverse effect of

If this precaution is neglected

impurities results in reduced yields of

labelled compound from the Sandmeyer reaction,
(ii)

4-Aminoquinoline Derivatives

The preparation of 4,X-diaminoquinoline derivatives (X
or 7) was planned because the X-amino group can be replaced

= 5, 6
selectively

1 3 1

with a

I labelled iodo group through the Sandmeyer reaction while

the 4-amino group is resistant to diazotisation.

Since 4-amino-

quinoline derivatives can be obtained by the reaction of the
corresponding 4-chloroquinoline derivatives with ammonia or a primary
amine it was intended to synthesise the diaminoquinolines from the
respective 4-chloro-X-nitroquinolines and to reduce the nitro group
at an appropriate stage of the preparation.

With a view to preparing

I labelled compounds by isotopic exchange as well it was planned
to synthesise the 4-amino-X-iodoquinoline derivatives (X = 5, 6
or 7).

They can be readily prepared from the respective 4-chloro-X-

iodoquinolines because the 4-halogeno group is preferentially replaced
by reaction with ammonia or amines while the X-halogeno group is not.
Consequently the initial steps in the synthesis were directed towards
the preparation of the 4-chloro-X-iodoquinolines.
(a)

4-Chloroquinoline Derivatives

Initially the preparation of the 4-chloroquinoline derivatives
was attempted from the corresponding quinoline derivatives by the
introduction of a chloro group in the 4 position following

selective

35
nitration of the N-oxide in this position.
selected because it was believed to

This route WHS

be the best method of general

application to any quinoline derivative whereas other methods led
either to mixtures of isomers in some cases or did not result in the
5-substituted quinoline derivatives e.g. ethoxymethylene malonic ester
43
method.

The scheme outlined in Fig.3b was followed in which the

appropriate quinoline derivative (14) was oxidised to the N-oxide (15)
from which the 4-nitroquinoline-l-oxide derivative (19) was obtained
by selective nitration.

The 4-chloroquinoline derivative (16) was

formed on reduction with phosphorus trichloride.

The experimental

conditions selected for the reactions were the ones claimed in the
literature to be successful under most circumstances e.g. peracetic
acid^^ was preferred to monoperphthalic acid for the oxidation of
quinoline derivatives to the N-oxides because of the reported failure

FIG. 4a. COURTAULD ATOMIC MODEL OF 4-NITRO-5-IODOQUINOLINE

FIG. 4b. COURTAULD ATOMIC MODEL OF 4-CHLORO-5-IODOQUINOLINE

to obtain 8-nitroquinoline-l-oxide by the latter reagent.

In

addition it was found necessary to isolate the crude 4-chloroquinoline
derivative by precipitation of the free base instead of the recommended
solvent extraction technique^^ because the extraction characteristics
of the substituted quinolines were poor.
The synthesis of the 5-nitro,6-nitro and 7-nitro derivatives of
4-chloroquinoline was accomplished by this method but the

final

step in the preparation of 4"Chloro-5-iodoquinoline failed to produce
the required compound.

In this case treatment of 4-nitro-5-iodo-

quinoline-l-oxide with phosphorus trichloride only reduced the N-oxide
function (i.e. without replacement of the 4-nitro group), and resulted
in 4-nitro-5-iodoquinoline.

Since the previously attempted prepara-

tion of 4-chloro-5-iodoquinoline had failed due to the formation of a
halogen free product when 2-carbethoxy-3-methyl-4-hydroxy-5-iodo41
quinoline was hydrolysed

it was clear that the synthesis of some

peri substituted 5-iodoquinoline derivatives was impeded.

Further

evidence of this can be seen (Fig.4a and 4b) from Courtauld atomic
models of 4-nitro-5-iodoquinoline and 4-chloro-5-iodoquinoline.
Because deformation of the quinoline ring is necessary to accommodate
the steric

configuration of 4-nitro-5-iodoquinoline then considerably

greater deformation is required for 4-chloro-5-iodoquinoline.

In

view of the steric difficulties synthesis of this latter compound
by standard methods is unlikely to be successful.

TABLE 1
ALTERNATIVE PREPARATIVE ROUTES TO 4,5-DINITROQUINOLINE-l-OXIDE FROM QUINOLINE
Product

Yield (%)

Yield (7o)

Product

5-Nitroquinoline

45

Quinoline-1-oxide

90

5-Nitroquinoline-l-oxide

74

4-Nitroquinoline-l-oxide

60

4,5-Dinitroquinoline-l-oxide

64

4,5-Dinitroquinoline-l-oxide

50
u>

Ln

Overall

yield

21

Overall yield

27

Whilst this preparative route did lead to the required 4-chloroX-nitroquinolines, shortcomings were apparent in the synthesis of
individual compounds.

In the preparation of 4-chloro-5-nitroquinoline

improvements can be brought about by a change in the order of reactions
(Table 1).

Instead of following the sequence of reactions leading

from quinoline to 4,5-dinitroquinoline, quinoline-l-oxide was prepared
first then nitrated in the 4 position before introduction of the
5-nitro group.

In another example an improved yield

( 6 8 7 o )

of

6-nitroquinoline-l-oxide has been obtained by oxidation of 6-nitroquinoline with monoperphthalic acid^^ instead of peracetic acid;
latter gives low yields

( 2 7 7 o )

the

due to the formation of by products

reported to be 6-nitro carbostyril and its N-oxide.^^
In spite of the successful preparations achieved by this route
it cannot be regarded as a satisfactory approach to the synthesis of
the 6-nitro and 7-nitro derivatives of 4-chloroquinoline because the
overall yields of these compounds from the respective nitroanilines
were exceptionally low (Table 2).

Consequently an alternative route

was sought to prepare these 4-chloroquinoline derivatives and the
43
ethoxymethylene malonic ester method of Price and Roberts
was selected.

(Fig.3d)

This method forms the 7 substituted quinolines almost

exclusively from meta substituted anilines.

Since 4-chloro-5-

nitroquinoline had already been satisfactorily prepared by the first
route this offered a particular advantage over quinoline synthesis by
the Skraup reaction and the Conrad Limpach method where 5 substituted

TABLE 2
COMPARISON OF THE YIELD OF 4-CHLORO-6-NITROQUINOLINE AND 4-CHLORO-7-NITROQUINOLINE
FROM 4-NITROANILINE AND 3-NITROANILINE

Initial Compound

3-nitroaniline

4-nitroaniline

Product

Yield (7o)

Product

Yield (7o)

Skraup reaction

6-Nitroquinoline

54

7-Nitroquinoline

10

Oxidation (acetic acidperoxide)

6-nitroquinoline1-oxide

27

7-Nitroquinoline-loxide

49

Nitration

4,6-dinitroquinolinel-oxide

32

4,7-Dinitroquinolinel-o xLde

46

Reduction &. replacement
of 4-nitro-group

4-chloro-6-nitroquinoline

72

4-chloro-7-nitro
quinoline

85

Reaction

Overall Yield

3.4

1.9

OJ

quinoline constitutes a major proportion of the product.
The scheme followed is shown in F i g . 5 where 3-nitroaniline

(29)

is condensed with diethyl ethoxymethylene malonate (25) and the
resulting acrylate (30) cyclised to 3-carbethoxy-4-hydroxy-7nitroquinoline (31).

Hydrolysis of this ester followed by thermal

decarboxylation produced 4-hydroxy-7-nitroquinoline

(34) which was

converted to the 4-chloro derivative (35) in the usual w a y .

It was

anticipated that the overall yield of 4-chloro-7-nitroquinoline would
be low w h e n prepared by this method since it depended on the
decarboxylation of the 3-carboxy-4-hydroxy derivative (32).

This

prediction is based on the fact that the preparation of 4-chloro6-nitroquinoline described in the literature^^ gave little better
than nominal yields of 4-hydroxy-6-nitroquinoline by decarboxylation.
By first converting the acid to its silver salt (33), improved yields
in the thermal decarboxylation of the 3-carboxy-4-hydroxyquinoline
72
derivative were obtained

and by employing this technique the poor

( -<107o) yield of 4-hydroxy-7-nitroquinoline

(34) was lifted to 547o.

The low yields encountered in the preparation of 4-chloro-6-iodo and
4-chloro-7-iodo quinoline by this method occurred on decarboxylation
of 3-carboxy-4-hydroxy-6- and 7-iodoquinolines.

However they were

comparable with those previously reported in the literature^^ and may
be due to decomposition with the release of iodine v a p o u r .
(b)

Introduction of the Amino Group into the 4 Position

The formation of derivatives of 4-aminoquinoline from the
4-chloroquinoline derivatives already synthesised by replacement of

NO

0

c(COOC2H5)2
+
NH2

(29)

cicOOCzHs)

CH
I
OC2H5
(25)

2"5

(33)

NOa^QIQ
(34)

CI

NO

oTo
N

(35)

FIG. 5

PREPARATION OF 4-CHLORO-7-NITROQUINOLINE BY THE DIETHYLETHOXYMETHYLENE
MALONATE METHOD.

the chloro group occurred readily with ammonia.

This was achieved

in all cases in phenol solution and usually at refluxing temperature
( 1 7 0 - 1 8 0 ° )

except in the case of 4-chloro-5-nitroquinoline when below

average yields were obtained under these conditions.
the reaction was carried out at a lower temperature

If, however,
( 1 4 0 - 1 5 0 ° )

yield of 4-amino-5-nitroquinoline increased to above

the

707o.

Where a secondary amino group with a particular side chain was
required in the 4 position an excess of the appropriate primary amine
was reacted with the 4-chloroquinoline derivative.

4-(3-Dimethyl-

aminopropylamino)-7-nitroquinoline was easily obtained from 4-chloro7-nitroquinoline in this way but the similar reaction of 4-chloro6-iodo and 4-chloro-7-iodoquinoline with 3-dimethylaminopropylamine
did not proceed as readily and a more intensive purification was
required to remove starting material from the product.
(c)

Preparation of 4,X-Diaminoquinoline Derivatives

Two approaches were considered to prepare the 4,X-diaminoquinoline
derivatives from the 4-chloro-X-nitroquinolines.

In the first one it

was intended to reduce the X-nitro group to the amino group before
introducing the second amino group at the 4 position.
initial experiments to reduce the nitro group

However the

by a number of methods

proved unsuccessful, e.g. hydrogénation with palladium catalyst
resulted not only in reduction but also in dehalogenation.

It j^as

clear that this approach had not taken the reactivity of the 4-chloro
group into account;

therefore reduction of the nitro group without

removal of the chloro group was unlikely to be successful.

Consequently the alternative method, i.e. replacing the chloro
group by the amino group before reduction of the nitro group, was
attempted.

It was intended to employ stannous chloride for the

reduction of the nitro group in the 4-amino-X-nitroquinoline
73
derivative because of its reported application for this purpose.
The preparation of 4,6 diaminoquinoline and 4,7-diaminoquinoline
derivatives by this method met with immediate success but 4-amino5-nitroquinoline was not reduced to 4,5-diaminoquinoline.

However

hydrogénation over palladium with acetic acid as solvent gave the
mono acetate salt of 4,5-diaminoquinoline which after sintering above
100° finally melted at 172-173°.

The infra red spectrum of the salt

showed absorptions at 2900, 1620, 1540 and 1400 cm"^ which were
indicative of protonated amine and carboxylate ion.

In the n.m.r.

spectrum of the salt there was a three proton singlet atôl.93
(MeCOO ) and a broad signal of five protons at Ô8.0 which disappeared
on exchange with deuterium oxide.

The aromatic proton signals were

present as two doublets (J = 6.5 Hz) atô8.82 andô6.65 (H2 and H3),
a quartet

= 7.0 and 1.5 Hz) atô6.94 (H8) and a two proton multiplet

at 57.1-7.7.

On warming the acetate salt in the probe of the mass

spectrometer, a strong signal at '^/e 60 (CH^COOH) was generated and
on further heating a strong signal ^/e 159 (4,5-diaminoquinoline parent
ion) appeared.
(iii)

Replacement of an Amino Group through Diazotisation
(a)

Preparation of Hydrazinoquinoline

Hydrazinoquinolines offer the most suitable method for the

introduction of tritium in a specific location on the quinoline ring.
Diazotisation of a primary amine followed by reduction of the diazo74 75
nium salt produces the hydrazino derivatives

'

which after exchange

of the active protons decomposes to the tritium compound.

The

hydrazino derivatives of 4-aminoquinoline were prepared in this way
by taking advantage of the resistance to diazotisation shown by the
4-amino group in 4,X-diaminoquinolines e.g. 4-amino-6-hydrazinoquinoline was prepared from 4,6-diaminoquinoline in this way.
(b)

Preparation of lodoquinoline Derivatives through
the Sandmeyer Reaction

Aryl diazonium salts react rapidly with iodide (or

) ions

in mineral acid solution to form the corresponding iodo compound,^^
Although this reaction is classified as a Sandmeyer reaction it does
not require cuprous iodide to facilitate this replacement.

This

method is particularly useful when employed to prepare the iodoquinolines from the respective monoaminoquinolines since the products
are steam volatile and so are capable of isolation in high purity.
5-iodo and 6-iodoquinoline which are well known solids were prepared
by this route in addition to 7-iodoquinoline which is an oil at room
temperature and is not as well characterised^^ e.g. the hydrochloride
isolated here is not reported in the literature.
Since diazotisation of 4,6-diaminoquinoline is known to take place
preferentially at the 6-amino group a similar preference on the part
of 4,5-diaminoquinoline and 4,7-diaminoquinoline was expected to allow
the selective introduction of the iodo group into the 5 and the 7

positions as well.

In fact, by using reagents in equimolar proportions

to reduce the possibility of reaction by the second amino group, 4-amino7-iodoquinoline respectively 4-(3-diinethylaminopropylamino)-7-iodoquinoline were formed from the corresponding 7-aminoquinoline derivatives
in good yields.

However, unlike the 6-amino and 7-amino compounds, no

iodoquinoline could be extracted from the basified solution following
the diazotisation of 4,5-diaminoquinoline and subsequent treatment with
potassium iodide.
was obtained;

When the solution was adjusted to pH 6.5 a precipitate

this was soluble both in acid and in alkali, which

suggested that one of the amino groups had been replaced by a hydroxyl
group to give a hydroxy quinoline derivative.

This can be explained

by successful competition of water against the bulky iodide ion - a
consequence of steric hindrance in the peri position - in the nucleophilic
substitution reaction.
131
(c)

Preparation of

I Labelled Iodoquinoline Derivatives

131
The use of

I to prepare labelled quinoline derivatives introduced

a number of problems not normally encountered in preparative organic
chemistry.

Because of the high radiotoxicity of this nuclide,

special precautions must be employed to avoid ingestion of the compounds.
As 131 I emits gamma and hard beta radiation the chemical techniques are
restricted to those which can be carried out by remote handling methods.
131
To minimise the hazards it is desirable to introduce the
possible, as the last step in the preparation sequence.

I, if
Even though

this process may lead to employing chemically inefficient procedures
for the preparation of the labelled material, nevertheless it had been

^^^Te (B,r)

''^e P —

(T, 2 x 10^ years)
2

^^^Te (n,r)

Fig.6

OF

131

^^^Te P —

(T, 8 days)

NUCLEAR REACTIONS LEADING TO THE FORMATION

I, STABLE AND LONG LIVED NUCLIDES OF IODINE.

accepted from the very beginning that safety was paramount to other
considerations.
It has already been demonstrated in this work that the required
iodoquinoline derivatives can be prepared by replacing an amino group
through the Sandmeyer reaction with non-radioactive iodide.

In order

to prepare labelled compounds with a controlled high specific activity
131
It was necessary to know accurately the specific activity of the
solution to be used in the Sandmeyer reaction.

I

It is often assumed

that radioiodine solutions contain only iodine corresponding to the
131
radioactive nuclide (which for
I is about 8 |ig per Curie). However
131
the

I available for this work contained iodine from other sources,

in particular as an impurity in materials and reagents employed in the
chemical separation of this nuclide and as a result of certain nuclear
131
reactions also occuring during the reactor production of

I (see Fig.6.).

Consequently a number of micro methods reported for the determination
of iodine concentrations^^'^^'^^ were tested.
131
of iodine determined in

From the concentration

I solutions (about 300 |ig/ml for a range of

concentrations from 100 to 1000 mCi/ml) it can be seen that the lowest
specific activity is 42 mCi per |i Equiv. of iodine.

As it was intended

to use these radioiodine solutions in the preparation of moniodoquinoline derivatives of 5 mCi per |iM specific activity it was necessary to add the appropriate quantity of potassium iodide carrier to
each radioiodine solution to lower its specific activity to 5 mCi per [i
Equiv.

By use of the radioiodine solutions the labelled iodoquinolines

and the 4-amino-iodoquinoline derivatives were readily obtained through

TABLE 3
131
RADIOCHEMICAL PURITY OF

I LABELLED QUINOLINE DERIVATIVES.

(Sterile solutions of 5 mCi/(iM specific activity at room temperature)
Quinoline Derivative

Time after
Labelling
(days)

5-Iodo

6-Iodo
7o of

0
1
3

99
-

96

99
-

7-Iodo
131

4-Amino-6-Iodo

4-Amino-7-Iodo

4- ( 3-dimethylaminopropylamino)-7-Iodo

I in required chemical form
99

89

90

99

92

90

-o
-

89

-

-

-

-

-

98

-

-

-

-

-

4

-

-

5

94

-

-

88

the Sandmeyer reaction on the 5 M-M scale.

Although the former compounds

could be isolated by steam distillation, separation of the latter ones
w a s more d i f f i c u l t .

Ultimately they were isolated by extraction into

chloroform.
131
W i t h the exception of the rather labile 5-iodoquinoline-

I which

showed progressive breakdown over a number of days, the autoclaved
solutions of the iodoquinolines were almost radiochemically pure (Table 3)
On the other hand the radiochemical purity of the 4-amino-X-iodoquinoline
derivatives was not as high as could be d e s i r e d , although they were
stable in solution at room temperature showing no evidence of breakdown
on storage.

The low values found for the radiochemical purity of the

labelled 4-amino-X-iodoquinoline may be attributable to the characteristics of the analytical method employed.

A modified
t.l.c. procedure
81

80

based on reported chromatographic methods
of the m a n y quinoline derivatives both
iodide ions.

'

gave excellent separations

from each other and also from

H o w e v e r , the 4-amino-X-iodoquinolines were not separated

from iodide as satisfactorily as the iodoquinolines and the small
tailing of radioactivity found could not be assigned

unambiguously.

This tailing and the contribution from the breakdown of the more
sensitive amino compounds on the highly active surface was responsible
for the apparently low radiochemical purity.
(iv) Radioactive Labelling by Exchange
131
(a)

I Labelled Compounds

In contrast to the Sandmeyer reaction where the specific activity
of the labelled compound is controlled by adjusting the specific

activity of the radioiodine used to replace the primary amino group,
labelling by exchange is limited by the rate of the exchange

reaction.

W h e n the exchange reaches e q u i l i b r i u m i.e. w h e n there is a u n i f o r m
.J-.
. .
^ Z radioiodine
specific activity of ^ iodine

-

, ,
b o t h product and reactants,

the m a x i m u m specific activity of the product is attained.

If isotopic

exchange occurs too readily, the lability of the radioactive

group

w o u l d lead to r a p i d loss of a substantial p r o p o r t i o n of the label in
the biological system.

In the case of

4-(3-dimethylaminopropylamino)131

7-iodoquinoline, exchange of the 7-iodo group w i t h

I iodide

took

place only slowly even in a h i g h boiling solvent such as ethylene
glycol.

This homogeneous isotopic exchange is described by the

equation:
RI

+

w h e r e RI represents

R^^^I

+

I

4-(3-dimethylaminopropylamino)-7-iodoquinoline.
82

A c c o r d i n g to the k i n e t i c treatment of Wahl and Bonner

and that of

C h a r l t o n 83
R ^^^ I

RI

J a
131^- .

R

bL
RI

if the exchange r e a c t i o n w a s carried out for a set period and, except
131
for the specific activity of
occasions

I, under fixed conditions o n two

(a'and'b*).

131

In the present w o r k , the initial quantity of RI was 100 mg and R
is about 0.1 |ig in each case, therefore the concentration of RI can
RI
be considered unchanged from the initial value i.e. [ RI_
Jb

I

The values for the other quantities on each occasion were:
a

b

I

8 mCi

6 mCi

131 I-

17 mCi

144 mCi

15 fig

180 fig

131
R

l"

Substitution of the above values in the equation shows that the
131
amounts of

I incorporated into the labelled compound on each

occasion are consistent with each other.

Furthermore the second

labelling attempt 'b' illustrates the weakness of the exchange method:
131
when a greatly increased quantity of

I (150 mCi) was used, in

contrast to 25 mCi used the first time, less radioiodine was incorporated
into the compound.

Under the particular conditions employed, a higher

specific activity product could only be obtained if higher specific
activity 131 I were used in the exchange.
Once it has been shown that a compound can be labelled with
131
I by homogeneous isotopic exchange then heterogeneous isotopic
exchange of the radioactive iodo group with e.g. chloride ions, can
be expected to take place also.
radioactive label.

This would result in the loss of the

The rate at which the latter exchange proceeds is

particularly important in the case of radioactive labelled quinoline
derivatives for parenteral injection as solutions of these compounds
also containing sodium chloride are sterilised by autoclaving. This
131
was demonstrated by autoclaving a solution of
I labelled 4-(3dimethylaminopropylamino)-7-iodoquinoline

increase was found in

131

(i) in citric acid when no

I in the form of free iodide and (ii) in

hydrochloric or sulphuric acids where there was an increase on autoclaving in the proportion of

131

I exchanged.

The reason for this is

the absence of exchangeable ions from the citric acid solutions.

In

all cases where additional chloride ions had been added much larger
131
portions of

I were exchanged.

The significance of this result is

that labelled quinolines for testing in experimental animals must be
prepared in solutions containing non exchangeable ions if they are to
be sterilised by autoclaving.

The distribution of radioactivity

determined experimentally in the animal body will not represent
accurately the distribution
of the labelled compound if a significant
131
proportion of the
I in the administered material is in the form of
131
iodide ions.

I labelled quinolines which required sterilisation

by autoclaving prior to injection into animals, were formulated in an
acetate buffer solution containing no halogen anions.
It had been anticipated that iodide ions could be removed from
solutions
labelled
quinolines
absorption
on anion exchange resin.
In
fact, aof
single
passage
of 131 Iby
labelled
4-(3-dimethylaminopropylamino)
-7-iodoquinoline in citric acid solution through a column of ion exchange
131
resin lowered the proportion of
five passages to less than

O . 5 7 o .

I as iodide ions from

97o

to

4.57»

and

However, while this procedure can be

employed to improve the radiochemical purity of solutions to be given
orally, anion exchange resins have been found to be a source of
pyrogenic material and solutions treated with them may not be injected
parenterally unless tested for apyrogenicity by the standard British
Pharmacopoeia method.

(b)

H Labelled Compounds

Quinoline derivatives labelled in the benzene ring were prepared,
by an isotopic exchange method, from the hydrazinoquinoline derivative
in which the hydrazino group is decomposed after the exchange of the
active protons.

This procedure has the advantage of introducing the

tritium label at a specific position on the quinoline ring.

Alter-

native methods for the labelling of quinolinederivatives reported in
84
the literature

have relied either on electrophilic tritiation in

hot sulphuric acid solution, tritiation by exposure to tritium gas
(Wilzbach method) or on catalytic dehalogenation of a halogenoquinoline
derivative with tritium gas.

However the exchange methods have been

84
reported

to introduce tritium in all the susceptible positions on

the quinoline ring and result in a compound labelled in a number of
positions.

Catalytic dehalogenation can clearly be used to introduce

tritium into a selected position by replacement of a halogeno group
but experimental details and the results obtained have not been
described therefore the value of the method cannot be adequately
assessed.
Initially it was attempted to prepare 4-aminoquinoline-6- 3H from
4-amino-6-hydrazinoquinoline but only nominal yields were obtained so
3
instead quinoline-5- H was prepared from 5-hydrazinoquinoline.
3
3
4-Aminoquinoline-5- H was synthesised from the quinoline-5- H through
quinoline-l-oxide, its 4-nitro derivative and 4-chloroquinoline.
This method was chosen because the conditions normally used for the
catalytic reduction of 4-nitroquinoline-l-oxide to 4-aminoquinoline

are conducive to catalytic isotopic exchange and therefore result
in loss of the tritium label.
(v)

Correlation of Spectral Data
Infra Red Spectra

Confirmation of the presence of functional groups and establishing the identity of the products from microscale preparations was
predominantly carried out by comparison of the infra red spectra of
the quinoline derivatives w i t h the spectra obtained from authentic
specimens.

Comparisons were made w i t h a number of absorption

frequencies published previously for nitroquinolines, for halogenoq u i n o l i n e s ^ ^ , and for a wide range of 4-substituted quinolines^^ and
w i t h assignments of the ring stretch bands and the in plane and out
of plane CH deformation frequencies published for monosubstituted
87
quinolines.

While the 4 - , 5 - , 6 - , and 7- monosubstituted

quinolines

display ring stretching absorptions which correlate w e l l , in the range
1630-1550 cm

w i t h the published values there is no similar correlation

either in the 1500-1350 cm ^ region or for the in plane and out of
plane frequencies at 1300-800 cm

All the absorption
frequencies
87

reported for monosubstituted quinoline derivatives
in the compounds examined.

However not all the frequencies were

identified in every compound.
in detecting low intensity

were present

This was attributable to the difficulty

absorptions.

One feature emerging from an examination of the infrared spectra
of the 4,X-disubstituted quinoline derivatives and their N-oxides is
a relationship between the X position and the absorption frequencies

at about 800 cm

The 4,5 disubstituted derivatives have two

prominent absorption peaks between 850 cm ^ and 810 cm

the

4,7 derivatives absorb at about 830 cm ^ with a stronger absorption
frequency at about 800 cm

while the 4,6 substituted ones absorb

at one of the latter two frequencies.

In the few 4,6 substituted

compounds absorbing at both 800 and 830 cm"^ it was the 800 cm"^ band
which had the lower intensity.

Although the number of compounds

studied is not large, these differences may give a method of
distinguishing between 4,6 and 4,7 substituted quinolines.
In a spectral investigation published previously strong
absorption in both the 1350 cm ^ and the 1190 cm ^ regions was
86
attributed to the N-oxide function in quinolines.

All the

quinoline-l-oxide derivatives examined in this work (Table 4)
absorbed (in addition to bands characteristic of the functional
group) both in the 1190 cm ^ region and in the 1350 cm ^ region
but the band at 1190 cm ^ was neither particularly prominent nor
was it unique to the N-oxides.

Although the individual frequencies

of the N-oxides may be related in a systematic way to substitution
in particular positions, too few compounds were studied here to
permit definite assignment of any of the individual peaks to a
particular pattern of substituents.

TABLE 4
PROMINENT ABSORPTION FREQUENCIES OF QUINOLINE AND DERIVATIVES
650 - 900 cm
Quinoline

730m

752w

777m

796s
800m

5-Nitroquinoline

712w

728m

767m

788m

7-NitroquinoIine

720m

753m

777w

787s

4-Aminoquinoline

716s

747m

774w

5-Aminoquino1ine

702m

720w

760m

800vw
770s

6-Aminoquinoline

715w

755m

7-Aminoquinoline

715w

755m

779w

5-IodoquinoIine

727m

750vw

792s

7-Iodoquinoline hydrochloride

720w

757m

Quino1ine-1-oxide

835m

886m

825m

875m

820w

877w

803m
820s

850w

824s
828w

878m

790m

875s

777w

865w

735m

762w

7-Nitroquinoline-l-oxide

718w

728m

755s

735m

770w

775s

870w

846s

768m
715s

885w

830s

840s

5-Nitroquinoline-l-oxide

5-Iodoquinoline-l-oxide

-1

810s

870w

873m

4,5-Dinitroquinoline-l-oxide

716w

735m

753m

775s

825m

837m

4,6-Dinitroquinoline-l-oxide

715w

737m

762vw

788s

846s

856s

4,7-Dinitroquinoline-l-oxide

724m

764m

790s

825w

845m

865m

750m

847s

896s

4-Chloro-5-nitroquinoline

700w

715w

4-Chloro-6-nitroquinoline

675w

716w

4-Chloro-6-iodoquinoline

670m

713m

735m

813s
797m

760w

833m

810w
820m

835s

867m

4>

TABLE 4 (contd.)
4-Chloro-7-nitroquinoline

675w

715w

4-ChIoro-7-iodoquinoline

670m

720wb

735s
760m

4-Amino-5-nitroquinoline

725m

750m

4-Amino-6-nitroquinoline

716vw

740s

4,6-Diaminoquinoline

720m

4,7-Diaminoquino1 ine

677m

725m

767w

4-Amino-6-iodoquinoLine

653w

717s

763m

715m

757w

697vw

744m

4-Amino-7-iodoquinoline
4- ( 3-Dimethy Lamino-propy
amino)-7-aminoquino1ine

65 3w

4-(3-DimethyLamino-propylamino)-7-iodoquino1 ine

717w

3-Carboxy-4-hydroxy-6iodoquinoline

720w

740w

800m

825m

845m

805s

835w

840m

813w

827s

845m

855s

875s

895w

795w

830s

877w

774m

827m

886w

806s

823w

857s

820s

880w

801m

825w

865w

763vw

778w

813vw

843m

767m

793m

813w

838w

875w

883w

850w

870w

v-n

Ln

5-Hydrazinoquinoline dihydrochloride

688m

720vw

740vw

4-Amino-6-hydrazinoquinoLine
dihydrochloride

668vw

690w

738w

750w

787m

828s

792s
765vw

795w

929m

5-Nitroquinoline

945m

7-Nitroquinoline

1025m
965w

897w
890m

830m

900 - 1200 cm
QuinoLine

880w

850m

-1

1110m

1135W

986w

1024w

1067m

1120m

1135W

932w

974w

1008m

1053m

lllOw

1124w

4-Aminoquinoline

936w

964m

1013w

1072w

5-Aminoquinoline

929w

993w

1030m

1060m

1143m

1160m
1185W

TABLE 4 (contd.)
6-Aminoquinoline

902m

955m

7-Aminoquinoline

913w

964m

1033w

5-Iodoquinoline

942w

L044vw

1070VW

1135m

7-Iodoquinoline hydrochloride

938s

1030W

1045m

1140W

1153m

1198m

Quinoline-1-oxide

967w

978w

1145m

1186m

955m

978m
978m

5-Nitroquinoline-l-oxide

927w

7-Nitroquinoline-1-oxide

910w

902w

4,6-Dinitroquinoline-l-oxide

900w

4,7-Dinitroquinoline-1-oxide

902vw

4-Chloro-5-nitroquinoline

924w

95 3w

917m

4-Chloro-6-nitroquinoline
4-Chloro-6-iodoquinoline
4-Chloro-7-nitroquinoline

904m

4-Amino-6-nitroquinoline

1154w

1102w

1140m

1177w

1091s

1135m

lOOOw

1013w

1057w

1125W

1198w

1029m

1070m

1128w

1190m

1062w

1114w

978w

987w

1070W

1097w

960vw

99 3w

105 3w

1094w

987w

1037w

1097w

1189m
1135W

1140m

975m

1068w

1143w

980m

1083m

1130VW

1159w

1190m

1159m

1179m

1160W

1180W
1190m

970m

1040W

917w

973w

1050w

1075W

1135W

1183m

963s

1050m

1063w

1140w

1180w

1068vw

1144vw

1080m

1130m

968w
1007w

907w

1175s

1090W

4,6-Diaminoquinoline
946m

4,7-Diaminoquinoline

1190W

957w

4-Chloro-7-iodoquinoline
4-Amino-5-nitroquinoline

1140m

1050m

5-Iodoquinoline-l-oxide
4,5-Dinitroquinoline-1-oxide

1115m

4-Amino-6-iodoquinoline

908w

930mb

4-Amino-7-iodoquinoline

910wb

930wb

970mb

1190W
1190VW

1140W
1143m

1013w

1090W

1117m

1007wb

1065W

1095VW

1015W

1050VW

1097vw

1165W

1172w

1130W

1145wb

1165wb

1115W

ll50wb

1190m

C^

TABLE 4 (contd. )
4-(3-Dimethylaminopropylamino)-7-aminoquino1ine

940vw

948w

978w

1030m

1060VW

1090W

1125VW

1150m

1171m

4-(3-DimethyLaminopropylamino)-7-iodoquino1ine

900w

965vw

992w

1035W

1075W

1090W

1130m

1160W

1190w

3-Carboxy-4-hydroxy-6-iodoquinoline

918m

930m

1115W

ll53w

1187m

1094w

983m

5-Hydraz inoquinoline
dihydrochloride
4-Amino-6-hydrazinoquinoline
dihydrochloride

1103vw

1045W

940m

1200 - 1600 cm
Quinoline

1317m

1365m

1385m

5-Nitroquinoline

1330m

1340m

1358m

7-Nitroquinoline

1322m

4-Aminoquinoline

1300m
1260m

5-Aminoquinoline

1160W

1135m

1160m

1170m

1465W

1495VS

1565m

1490w

15l2w

1478w

1525s

1570W

1510m

1560W

1578m

1558m

1574m

1599m

-1

1425m

1337m

1305W

1395W

6-Aminoquino1ine

1230W

1276m

7-Aminoquinoline

1210m

1290m

5-Iodoquinoline

1210W

1315m

7-Iodoquinoline
hydrochloride

1220W

1303m

Quinoline-1-oxide

1202s

1225m

1260s

1310m

1340w

5-Nitroquinoline-l-oxide

1253m

1286m

1310m

1335s

1360s

7-Nitroquinoline-l-oxide

1255m

1300m

1336s

1355s

1330W
1316s

1488w
1416w

1330m

1425m

1492m

1396m

1420s

1595W

1513m

149 7mb

1365m

1595m

1500s

1558m

1515s

1550w

1558w

1885m

1515s
1500m

1525m

1497m

1518m

1588m

1593m
1578s

1528m

1570m

TABLE 4 (contd.)

5-Iodoquinoline-l-oxide

1253s

1290W

1337S

4,5-Dinitroquinoline-l-oxide

1250W

1297S

1330S

1344s

4 , 6 - D i n i t r o q u i n o l i n e - l - o x i d e 1250m

1285S

1297S

1320S

1343m

4,7-Dinitroquinoline-l-oxide

1297S

1322m

1338m

1396m

4-Chloro-5-nitroquinoline

1210W

1407W

1299w

4-Chloro-6-nitroquinoline

1288m

4-Chloro-6-iodoquinoline

1270W

1355S

4-Chloro-7-nitroquinoline

1234w

1288vw

1340m

1415W

4-Chloro-7-iodoquinoline

1280m

1288m

1340W

1408w
1427w

1275m

1322m

1347W

4-Amino-6-nitrequinoline

1218vw 1280S

1323s

1340m

1560m

1505W

1525S

1558w

1515m

1540S

1565W

1498m

1528m

1575m

1595m

1490m

1528mb

1575m

1517m

1567m

1545m

1560m

1494vw

1480m

1337m

4-Amino-5-nitrequinoline

1553w

1415W

1338m
1325m

1524s

1574m

1595S

1557VW

1495S

1597S

1540S

4,6-Diaminoquinoline

1225W

4,7-Diaminoquinoline

1230m

4-Amino-6-iodoquinoline

1210W

1247w

1285W

1335m

1295S

1328m

1275W

1300W

1275m

1323VW

1346vw

1270VW

1306m

1330m

4- ( 3-Dimethylaniinopropy lamine
1234w
7-iodoquinoline

1250W

1280W

1327w

3-Carboxy-4-hydroxy-6iodoquinoline

1250W

1280W

1340W

1280W

1310m

4-Amino-7-iodoquinoline

5-Hydraz inoquinoline
dihydrochloride

1545S

1570S

4,5-Diaminoquinolinemonacetate

4-(3-Dimethylaminopropyla m i n o ) - 7 - a m i n o q u i n o 1 ine

1580m

1515sb
1478m

1587w

1230m

1235W

1413VW

1477m

1505W

1575m

1515S

1540W

1580sb

1495m

l'537vw

1555m

1575m

1505VW

1565W

1570S

1595m

1415m

1495W

1540W

1575S

1537VW

1583sb

1525VW

1565m

1390m

1370W

1440m
1403vw

1362w

1505VW
1420W

1570wb

1595mb

TABLE 4

(contd.)

4-Amino-6-hydrazinoquinoline
dihydrochloride

1214s

1237s

1275W

1421w

1296w

1600 - 4000 cm
Quinoline

1604m

1627m

5-Nitroquinoline

1605wb 1650VW

7-Nitroquinoline

1620w

4-AminoquinoLine

1626w

1655m

5-Aminoquino1ine

1610m

6-Aminoquino1ine
7-Aminoquino1ine

2950-

1480sb

-1

3120wb
3140 -

3300vwb
3300 -

3700wb

3120 -

3280mb

3280 - 3540wb

1655m

3100

3240mb

3240

3340wb

1625m

1645m

3120

3230mb

3280

3450wb

1600W

1623s

3240 -

3460mb

3220 -

3550wb

3440mb

3500mb

3350 -

3450mb

3300 -

3530wb

1720w

1645m

3120 - 3240mb

5-Iodoquinoline
7-Iodoquinoline
chloride

I500sb

hydro-

1600m

1880wb

Q u i n o l i n e - l - o xLde

1650mb

5-Nitroquinoline-L-oxide

1650mb

7-Nitroquinoline-L-oxide

1608m

5-Iodoquinoline-l-oxide

1615W

4.5-DinitroquinoLine1-oxide

1960wb

2340 -

2700mb
3100 -

3600mb

3060W

3220 -

3270wb

1630W

3070m

3110W

3140

1625vw

3070W

3110w

3130w

3115W

3153w

31lOw

3130VW

4.6-Dinitroquinolinel-oxide
4.7-Dinitroquinoline-loxide
4-Chloro-5-nitroquinoline

1605m

1623w
1625W

3080w

3100VW

TABLE 4 (contd. )

4-Chloro-6-iodoquinoline

3060VW

4-Amino-5-nitroquinoline

1615W

4-Amino-6-nitroquinoline

1602m

1635m

3270 -

3650wb

3180mb

3340mb

3500m

3150mb

3350wb

3430s

3220mb

3260 -

3500sb

3100W

1615W

4-Chloro-7-iodoquinoline
1655s

2300 - 2500wb

1667s

4,5-Diaminoquinoline monoacetate

1620s

4,6-Diaminoquinoline

1620m

1665m

3520wb
3740wb

1920VW

1630 - 1760wb

4-Chloro-7-nitroquinoline

3320 -

3090VW

1627m

4-Chloro-6-nitroquinoline

3080VW

4,7-Diaminoquinoline

1623s

1650W

1660m

1900w

3050 -

3260mb

3350s

3370w

3420s

4-Amino-6-iodoquinoline

1635W

1655s

1715wb

1900VW

2680m

3140wb

3260wb

3350wb

3450m

4-Amino-7-iodoquinoline

1635W

1655s

1695W

1715W

1900wb

2350wb

3140mb

3340wb

3460m
o

4-(3-Dimethylaminopropy1amino)-7-aminoquino1ine

1610m

4-(3-Dimethylaminopropylamino)-7-iodoquino1ine

1620s

2790W

2840W

3-Carboxy-4-hydroxy-6iodoquinoline

1622s

1696s

2680VW

5-Hydrazinoquinoline dihydrochloride

1640m

1770W

4-Amino-6-hydrazinoquinoline dihydrochloride 1610sb 1640sb

V - very:

s - strong:

3100 -

3300wb

3300 -

3700sb

2960m

3080 -

3280sb

3280 -

3500sb

2740VW

3075W

3170W

3220W • 3250W

3100 -

3300wb

3320 -

3680wb

3160 -

3700vsb

1675W

m - medium:

w -

1900 - 2300wb

weak:

b - broad:

3050 - 3160mb

TABLE 5
PERCENTAGE DISTRIBUTION OF

ADMINISTERED AS A LABELLED

lODOQUINOLINE, IN THE BODY AND EXCRETA OF HOODED RATS
(200g approx)

5-Iodoquinoline

Time of Sacrifice
after injection
(hr)

24

72

48

6-IodoQuinoline

7-IodoQuinoline

96

96

96

Eyes

0.001

0.003

0.007

0.02

0.002

0.001

Skin (pigmented)

0.6

0.3

0.9

0.6

0.4

1

(30)

(20)

(30)

(20)

(10)

(3)

0.4

1

0.5

0.7

0.9

(30)

(20)

(25)

(10)

(10)

(3)

Blood

0.2

0.06

0.4

0.1

0.01

0.6

Gut

0.6

0.2

2

0.4

0.5

2

Heart

0.005

0.01

0.009

0.02

0.007

0.005

Kidneys

0.08

0.06

0.2

0.07

0.05

0.06

Liver

0.7

0.5

1

0.6

0.4

0.4

Lungs

0.03

0.03

0.09

0.02

0.004

0.02

Spleen

0.01

0.02

0.006

0.01

0.002

0.008

Stomach

0.2

0.1

0.4

0.1

0.07

0.02

Residual Carcass

13

11

24

13

15

11

Excreta

85

87

69

84

83

84

(cpm/g)

Skin (unpigmented)0.3
(cpm/g)

B.

THE DISTRIBUTION OF THE LABELLED MATERIALS IN EXPERIMENTAL ANIMALS
(i)

Monoiodoquinolines

Most of the radioactivity originating from labelled 5-iodoquinoline
was excreted from the rat's body w i t h i n 24 h o u r s .
the last time of measurement at 96 hours
traces appeared both in the

Thereafter, up to

after administration, only

faeces and the urine.

The same

distribution of radioactivity was found in rats from either 5 - , 6 - , or
7-iodoquinolines

(Table 5 ) .

Although w h e n administering either

labelled 6- or 7-iodoquinolines measurements were only made after 96
h o u r s , it can be safely a s s u m e d , by analogy with 5-iodoquinoline, that
they too were similarly excreted soon after administration.
Preferential concentration of the radioactivity remaining in
the body of the rat was not apparent in the pigmented tissues i.e.
in the eyes and in the coloured skin, at the end of the experimental
period.

The exception was 5-iodoquinoline for which a higher

concentration of radioactivity was found in pigmented than in nonpigmented skin (Table 6 ) , indicating some selective affinity for the
pigmented skin.

H o w e v e r , not only did the amount of labelled compound

behaving in this way represent a small proportion of the initial dose
but also the concentration of radioactivity in the pigmented skin
(cpm/g) was low indicating that the monoiodoquinolines display no
significant affinity for pigmented

tissue.

(ii) lodoaminoquinolines
Contrary to the initial expectations, the concentration of

131

I

TABLE 6
RELATIVE CONCENTRATIONS OF

131

I IN PIGMENTED AND NON PIGMENTED

SKIN OF RATS

131

I Labelled Quinoline

5-Iodoquinoline

Period in
animal (hr)

cpm/g pigmented skin
cpm/g non pigmented skin

24

1

48

1

72

1.2

96

2

6-Iodoquinoline

96

1

7-Iodoquinoline

96

1

in pigmented skin could not be used for the purposes of comparing
the diagnostic value of these compounds.

The reason for this is the

variation found in the intensity of skin pigmentation in individual
animals.

While all the animals used in these experiments possessed

deeply pigmented fur, the poorer skin pigmentation of some was only
apparent on dissection.

Concentration of labelled compounds in the

pigmented skin was indicative of a biologically active compound but
incorporation depends more on the degree of pigmentation than on
differences between the individual compounds,
(a)

In Rats

The affinity of labelled 4-amino-6-iodoquinoline and 4-amino7-iodoquinoline is high^ specific for pigmented tissue.

High

concentrations of radioactivity were measured in the eyes and pigmented
131
skin (Table 7) and the total amounts of

I in these tissues represent

a significant proportion of the dose of labelled compound administered.
Almost all the radioactive material not incorporated into the pigmented
tissue was excreted by the rats.

This indicates that the introduction

of the primary amino group into the 4 position of either 6- or 7-iodoquinoline is

responsible for the acquisition of the biological activity
18

It has been reported

previously that two thirds of the excreted

radioactivity (which is, on average, ITL of the total dose) appeared
in the urine following oral administration to humans of a single dose
of radioiodine labelled 4-(3-dimethylaminopropylamino)-7-iodoquinoline
although the nature of the radioactive compound excreted was not
established.

By contrast little radioactivity was found in the

TABLE 7
131

I DISTRIBUTION IN ORGANS AND CONCENTRATION IN TISSUES IN

HOODED RATS (200g approx) SACRIFICED AFTER 96 HOURS

4-Amino-6-iodoquinoline

Labelled Quinoline

intra peritoneal

Oral

|iM

0.01

0 .01

|LiCi

50

25

Route of Administration
Dose of Quinoline
administered

Eyes

2.5

2x10^

0. 3

tissue
conc.
(cpm/g)
4
2x10

Skin (Pigmented)

2

4x10^

0. 2

5x10^

Skin (Non Pigmented)

0. 6

3x10

0. 4

4x10^

Muscle

n. d.

10^

n. d.

5x10^

Blood

0. 02

3x10^

0. 008

2x10^

G.I.T.

0. 5

n.d.

0. 2

n.d.

Heart

0.02

5x10^

0.004

3x10^

Kidneys

0. 2

2x10^

0..02

4x10^

Liver

0.4

10^

0.09

4x10^

Lungs

0.03

6x10^^

0.01

2x10^

Spleen

0.05

2x10^

0.,005

2x10^

Fat

n. d.

n.d.

n.,d.

20

Residual Carcass

0. 9

n.d.

0,,7

n.d.

Excreta

90

n.d.

98

n.d.

7o

n.d. = not determined:
G.I.T. =

Gastrointestinal Tract

tissue
conc.
(cpm/g)

2

7o

TABLE 7 (contd.)

4-Amino-7-iodoquinoline
Oral

oral

intra peritoneal

O.OA

0.Ol

0.,01

100

50

25

7o

7o

tissue
conc.
(cpm/g)

7o

100

7o

tissue
conc.
(cpm/g)

0.4

1x10^

2

2x10^

0.3

tissue
conc.
(cpm/g)
4
2x10

0.2

4
4x10

2

5x10^

1

8x10^

0.2

3x10^

0.2

2x10^

3

2x10^

2

2x10^

0.2

4x10^

n.d.

3x10^

n.d.

3x10^

n.d

10^

n.d.

tissue
conc.
(cpm/g)

0.04

0.6

2x10^

O.Ol

4x10^

0.3

2x10^

0.04

8x10^

O.Ol

5x10^

0.2

n.d.

1

n.d.

0.7

n.d.

0.2

n.d.

0.001

2x10^

0.03

6x10^

O.Ol

2x10^

0.003

5x10^

0.02

7x10^

0.1

2x10^

0.05

8x10^

0.02

8x10^

0.07

9x10^

0.7

3x10^

0.4

2x10^

0.2

4x10^

0.009

5x10^

0.06

10^

0.02

5x10^

0.008

6x10^

0.002

3x10^

O.Ol

9x10^

O.Ol

3x10^

0.001

4x10^

n.d.

40

n.d.

n.d.

n.d.

90

n.d.

0.5

n.d.

5

n.d.

4

n.d.

1

n.d.

n.d.

n.d.

86

n.d.

92

n.d.

n.d.

n.d.

urine of rats following administration of either 4-amino-6-iodoquinoline
or 4-amino-7-iodoquinoline.

Both radioiodine labelled iodoquine

and

4-(3-dimethylaminopropylamino)-7-iodoquinoline are known to be
incorporated into pigmented tissue independently of the route of
administration, i.e. whether they were given orally or parenterally.
It has not, however, been previously determined whether the efficiency
of incorporation is rel ated to the route of administration.

In this

work the uptake of the iodoaminoquinolines in pigmented tissue was
shown to be 8 times higher when administered by intraperitoneal injection
than when given orally (Table 7).

Since it is unlikely that such a

great dependence on the route of administration would have been overlooked in the clinical trials reported,^^'^^ these results suggest
that compounds with an unsubstituted 4-amino group follow a different
metabolic path than those with certain secondary amino groups in the
4-position.
It is well known that chloroquine is degraded in the human body
when given orally.^^

Although the nature of the degradation products

is not fully known, there is de-ethylation to the corresponding
secondary amine, 4-(4-ethylamino-l-methylbutylamino)-7-chloroquinoline,
which is excreted in the urine.^^

Obviously derivatives of 4-amino-

quinoline possessing only a primary amino group cannot undergo this mode
of degradation.

As the metabolic pathways of the two groups of

compounds differ, it is not surprising to find excretion taking place
88
mainly by different routes.

It has been proposed

that,

4-(3-dimethylaminopropylamino)-7-iodoquinoline combines with glucuronide
in the liver and is concentrated in melanomas by the action of tumour

glucuronidase.

In order to establish whether the metabolism of the

labelled iodoaminoquinolines fits this proposal or, at least, to derive
information concerning the metabolic pathway followed, the progress
of the radioactivity through the body of the rat was monitored by
means of a gamma camera.
This technique showed, following oral administration of the
compounds, that :
(i)

after 8 hours the radioactivity was concentrated in the liver
(with smaller amounts in the thyroid and the upper
gastrointestinal tract)

(ii)

after 24 hours at least three quarters of the amount had
been excreted and the residue was mainly concentrated in the
intestines with traces in the thyroid, eyes and liver

(iii)

after 96 hours the residual radioactivity in the rat was
concentrated in the eyes and in the thyroid (with traces
only in the liver).

It was clear that the labelled compound which was absorbed from
the gastrointestinal tract was metabolised in the liver and, confirming
the finding earlier in this work, was predominantly excreted in the
faeces.

Whilst this evidence is consistent with some form of metabolism

in the liver it does not provide detailed evidence of the pathway by
which the radioactive material becomes incorporated in pigmented tissue,
(b)

In Tumour Bearing Mice

The metabolic fate of labelled 4-amino-6-iodoquinoline and 4-amino-7-iodoquinoline in tumour bearing animals was the same as observed

TABLE 8
I DISTRIBUTION IN ORGANS AND CONCENTRATION IN TISSUES IN
C-57 MICE WITH MELANOMAS

4-•Amino-6-iodoquinoline

Labelled Quinoline

oral

intra peritoneal

Route of Administration

2

3

No. of Mice in Group

7o

tissue
conc.
(cpm/g)

7o

tissue
conc.
(cpm/g)

Melanoma

3

4x10^^

0.5

4x10^

Eyes

1

3x10^

0.1

4x10^

Skin (Pigmented)

n.d.

6x10^

n.d.

4x10^

Muscle

n.d.

2x10

n.d.

10^

0.005

2x10^

0.001

60

n.d.

10^

n.d.

50

Blood
Bone
G.I.T.

0.07

n.d.

0.04

n.d.

Heart

0.07

7x10^

0.001

50

Kidneys

0.03

10^

0.002

Liver

0.09

10^

0.02

2x10^

Lungs

0.006

4x10^

0.003

2x10^

Spleen

0.004

4x10^

0.001

n.d.

4x10^

n.d.

2

n.d.

1

Fat
Residual Carcass

n.d.

=

10^

40
10^
n.d.

not determined

G.I.T. = Gastrointestinal Tract
Percentage distribution values are percentages of administered dose;
The remaining radioactivity is contained in the excreta which could
not be collected.
131
Each mouse given 10 |LiCi of

I labelled compound at a specific

activity of 5 mCi/|j,M and sacrificed after 96 hours.

TABLE 8 (contd.)

4-(3-dimethyiaminopropyiamino-/iodoQuinoline

4-Amino-7-iodoquinoline
intra peritoneal

oral

3

2

0.5

tissue
conc.
(cpm/g)
4
3x10

0.1

1

3x10^

n.d.

7o

intra peritoneal

7o

oral

5
tissue
conc.
(cpm/g)

7o

1

%

tissue
conc.
(cpm/g)

0.4

4x10^
4
2x10

0.1

tissue
conc.
(cpm/g)
4
2x10
4
2x10

3x10^

n.d.

2x10^

n.d.

3x10^

10^

n.d.

80

n.d.

2x10^

0.02

2x10^

n.d.

10^

n.d.

80

n.d.

2x10^

n.d.

2x10^

0.5

4x10^
4
3x10

9x10^

n.d.

n.d.

7x10^

n.d.

0.03

10^

0.004

n.d.

10^

0.5

0.05

60

0.4

n. d.

0.06

n.d.

2

n.d.

0.5

n.d.

0.008

8x10^

0.001

2x10^

0.04

6x10^

0.007

4x10^

10^

0.004

2x10^

0.1

8x10^

0.03

7x10^

0.1

2x10^

0.7

0.2

7x10^

10^

0.003

2x10^

0.04

6x10^

O.Ol

5x10^

0.006

7x10^

0.001

80

0.05

6x10^

0.004

3x10^

n.d.

2x10^

n.d.

n.d.

5x10^

n.d.

5

n.d.

0.5

1

n.d.

1

0.03
0.3
0.02

4x10^

10^
n.d.

30
n.d.

in healthy rats except that the radioactivity was concentrated not only
in the skin and eyes but also in the melanomas.

Furthermore, in

agreement with the previous results in rats, the compounds administered
131
parenterally resulted in an 8 times higher concentration of
the eyes and melanomas than after oral administration.

I in

Contrary to

this, the pattern of the uptake of 4-(3-dimethylaminopropylamino)-7iodoquinoline features higher concentrations in the melanomas following
oral administration (Table 8).

As it is unlikely that the metabolic

pathway is species dependent, the difference in biological effect
observed with substitution of the 4-amino group must be attributed
to the structural features of the molecule.
It has been reported

that the 6 and 7 positions of 4-(3-dimethyl-

aminopropylamino)-quinoline are equivalent for substitution by an iodo
group.

In fact, similar results were found for the incorporation of

radioactivity from 4-amino-6-iodoquinoline and 4-amino-7-iodoquinoline
into the eyes of rats and mice and for the distribution in other tissues
Table 8 shows that a five times higher proportion of the initial dose
of the 6-iodo compound accumulated in melanomas but this is simply
due to

the presence of larger tumours in those animals.

The

affinities of these compounds for the tumours, as represented by the
concentration of

is about equal confirming that, for substitution

by an iodo group, the 6 and 7 positions of 4-aminoquinoline are also
equivalent.
Lt could have been anticipated that either the affinity for
pigmented tissue or the rate of metabolism of the labelled compounds
would depend on the quantity of the quinoline derivative administered.

f.

FIG.7a

.

-....

• .•

'

GAMMA CAMERA DISPLAY OF MOUSE 96 HOURS AFTER A 30 ^iCi
ORAL DOSE OF 4-(3-DIMETHYLAMINOPROPYLAMINO)-7-IODOQUINOLINE-

^

»

t#

FIG.7b

ABOVE MOUSE PARTIALLY DISSECTED TO SHOW THE LOCATION OF THE
MELANOMA

131

TABLE 9
EFFECT OF SPECIFIC ACTIVITY ON TISSUE CONCENTRATIONS OF
RADIOIODINE FROM 4-(3-DIMETHYLAMINOPROPYLAMINO)-7-IODOQUINOLINE
IN C-57 MICE WITH B16 MELANOMA

10 |iCi of compound was administered to each mouse by i.p
injection.

All mice sacrificed after 96 hours

Dose of Compound (|iM)

3

0.002

Specific Activity of
Compound mCi/mM

3.2

Radioactive nuclide

125x

5,000
131i
cpm/g

Melanoma

4
8x10

4x10^

Eyes

5x10^

2x10^

Skin

2x10^

2x10^

Muscle

10^

80

Blood

2x10^

2x10^

Bone

n.d.

2x10^

Heart

5x10^

6x10^

Kidneys

5x10^

8x10^

Liver
6x10^

Lungs
/

Fat

r\

6x10

Spleen
3x10^

5x10^

The amount of radioactivity given to each animal in this work was the
same as had been used to obtain the results previously

reported.^^

However the specific activity of the compounds prepared here was much
higher than those previously available.

Therefore the actual quantity

of the quinoline derivative administered to each animal was considerably
smaller.

Compari son of the concentratioiB of

131

I in tissue reported

24
in this work with published results

obtained with low specific

activity 4-(3-dimethylaminopropylamino)-7-iodoquinoline showed that,
in fact, there is a dose dependence.

Less of the high specific

activity material employed here was found in all tissues, both in
pigmented and in non-pigmented ones, (Table 9).

However, it is just

as easy to distinguish between melanotic tumours and non pigmented
tissues in this case as with large doses of low specific activity
material.

This is demonstrated by the gamma camera oscilloscope display

(Fig.7a) where the melanoma is clearly differentiated from all other
tissues.

The same partially dissected mouse is also shown (Fig.7b)

to indicate the correlation between the radioactivity and the location
of the tumour.
3
(iii) 4-Aminoquinoline-5- H
This work has shown that the presence of a primary amino group
in the quinoline ring causes the labelled compounds to concentrate
in the eyes.

However, only slightly higher concentrations of radio-

activity were found in the eyes than in other tissues following the
administration of tritium labelled 4-aminoquinoline, i.e. a quinoline
derivative without a halogen substituent (Table 10).

The concentrations

TABLE 10
H CONCENTRATIONS IN TISSUES IN C-57 MICE WITH MELANOMAS
GIVEN 4-AMINOQUINOLINE-5- H

Sacrificed after 96 hours
Dose of Compound (fiM)

0.3

0.6
cpm/mg

Melanoma

2x10^

Eyes

4x10^

10^

Skin

4x10^

10^

Muscle

4x10^

3x10^

Blood

n.d.

3x10^

Bone

3x10^

20

Heart

2x10^

3x10^

Kidneys

2x10^

10^

Liver

3x10^

10^

Lungs

2x10^

80

Spleen

5x10^

4x10^

Fat

5x10^

4x10^

40

of tritium measured in the implanted melanomas were less than in many
non pigmented tissues.

It is

e/ident therefore, that in order to

achieve the selective affinity for melanotic tumours and pigmented
tissues, the presence of a halogen substituent is necessary in the
benzene ring of the quinoline ring system.

C.

IMPLICATIONS OF THE RESULTS
The outstanding feature common to the 4-aminoiodoquinoline

is their highly selective affinity for pigmented tissue.

derivatives

From the

point of view of ease of preparation the labelled compound that can be
given orally has two m a i n advantages:
(i)

it does not have to be completely apyrogenic as does a
solution for parenteral

(ii)

administration

a smaller amount of radioactive material is concentrated in the
eyes w h e n the compound is given orally.

The most successful compound given orally was 4-(3-dimethylaminopropylamino)-7-iodoquinoline.

Its ability to concentrate in pigmented

tissue is similar to that shown by 4-amino-7-iodoquinoline when given
by injection.

H o w e v e r , without clinical assessment, it is not clear

h o w the diagnostic value is affected by the difference in the routes
of elimination from the body of the two types of compounds.

Never-

t h e l e s s , whichever compound is preferred by the physician it can be
readily prepared by the method developed in this project namely, by
means of the Sandmeyer reaction from the corresponding primary amine.
In a d d i t i o n , the specific activity of the compound can be adjusted to any
desired v a l u e .
The clinical implications of the availability of labelled compounds
w i t h high specific activity are based on the rapid excretion of the
radioactive material from the body w h e n only small amounts of quinoline
derivatives (35 \ig per kg body w e i g h t ) are administered.

The most

important c o n d i t i o n , the ability to differentiate pigmented tissues from

TABLE

11

C A L C U L A T E D R A D I A T I O N D O S E R E C E I V E D BY THE EYE

FROM

V A R I O U S IODINE N U C L I D E S U N I F O R M L Y D I S T R I B U T E D

IN

THE IRIS A N D C H O R O I D A S S U M I N G R E T E N T I O N F O R THE

PERIOD

OF T O T A L D E C A Y OF THE N U C L I D E

Nuclide

123^

125^

131^

Half L i f e

13 h o u r

60 d a y s

8 days

Eye R a d i a t i o n D o s e
rads/fiCi

0.03

2

3

non pigmented ones, is not adversely affected - and may even be slightly
enhanced - under these conditions.

Consequently a patient would

receive a smaller radiation dose because of the more rapid clearance
of radioactivity from the body.
effectively before the 5 day delay

It may even be possible to scan
period used in current practice.

It is known that the critical organ in the body exposed to
radiation originating from the radioiodine labelled quinoline derivatives
is the eye.

The actual radiation dose received depends both on the

particular radioiodine nuclide employed and on the period it is resident
89
in the eye.

The calculations made

of the dose received by the eye

from various iodine nuclides assuming (for the purposes of the
calculation) that the radioactivity remained in the eye for the whole
period of total 125
decay of the nuclide are reported in Table 11.
Obviously some
elapsed.

I could be released before even one half life has

The actual radiation dose would therefore be less than the

calculated one although there is insufficient information at present
to predict the extent by which it would be reduced.
It can also be seen 123
that an even lower radiation dose can be
achieved by the use of

I in melanoma diagnosis.

would not have been considered possible.

Formerly this

But, because labelling with

radioiodine through the Sandmeyer reaction is a facile
procedure, the
123
use of this nuclide is now feasible because the
can be prepared immediately before use.

I labelled compound

In addition it is likely

that scanning too may be carried out earlier before excessive decay
of the nuclide has occurred by using material with high specific

activity.

Unfortunately

I is produced by means of a high energy

charged particle accelerator, e.g. a cyclotron, and is not yet readily
accessible in Australia.

However, elsewhere in the world the potential

application of this nuclide merits thorough examination.

EXPERIMENTAL

1.

GENERAL
Elemental

Microanalyses

M i c r o a n a l y s e s for c a r b o n , h y d r o g e n and n i t r o g e n w e r e carried o u t
by the A u s t r a l i a n M i c r o a n a l y t i c a l S e r v i c e , C S I R O , M e l b o u r n e .
Melting

Points

M e l t i n g p o i n t s w e r e d e t e r m i n e d in c a p i l l a r i e s on the B u c h i
a p p a r a t u s and are
I n f r a Red

uncorrected.

Spectra

T h e i n f r a red a b s o r p t i o n s p e c t r a of solid c o m p o u n d s w e r e o b t a i n e d
in n u j o l m u l l o n a P e r k i n E l m e r M o d e l 237 s p e c t r o m e t e r .

The

spectra

of l i q u i d c o m p o u n d s w e r e o b t a i n e d in a liquid film s a m p l e .
Nuclear Magnetic Resonance

Spectra

P r o t o n m a g n e t i c r e s o n a n c e s p e c t r a w e r e o b t a i n e d on a V a r i a n A 6 0
m a c h i n e at the U n i v e r s i t y of N e w S o u t h W a l e s .

Samples w e r e prepared

as 107o W / V s o l u t i o n s in h e x a d e u t e r o d i m e t h y l sulphoxide and chemical
s h i f t s (5) are q u o t e d in p p m d o w n f i e l d from t e t r a m e t h y l
( 6 = 0 . 0 0 0 ) as an i n t e r n a l
2.

silane

reference.

METHODS
T h i n Layer

Chromatography

The p r o g r e s s of all r e a c t i o n s w e r e m o n i t o r e d by thin layer
c h r o m a t o g r a p h y and q u a l i t a t i v e v i s u a l a s s e s s m e n t s w e r e m a d e of the
r e l a t i v e p r o p o r t i o n s of p r o d u c t s , by p r o d u c t s and r e a c t a n t s .

The

r a d i o c h e m i c a l p u r i t y of e a c h labelled compound w a s d e t e r m i n e d by
m e a s u r e m e n t of the d i s t r i b u t i o n of r a d i o a c t i v i t y along the thin layer
chromatogram.

E x c e l l e n t s e p a r a t i o n s of a l m o s t all the

substituted

quinolines involved in this w o r k were obtained on 100 |im layers of
silica gel w i t h fluorescent indicator (Eastman sheet 6060) developed
with

257o

V/V triethylamine in chloroform and visualised w i t h

Determination of

131

I and

3

U.V.

light.

H
131

The absolute rad ioactivity of

I in samples was measured by

determination of the ionisation current from the sample in a calibrated
4 TT gamma ionisation chamber or in the Nuclear Chicago Mediae dose
calibrator.
The relative radioactivity of animal tissue specimens containing
131

I w a s determined by counting each specimen at a fixed low geometry

from a Nuclear Chicago gamma scintillation counter.
concentrations in tissue of

131

The relative

I were determined by counting 50-100 m g

tissue specimens in a well-crystal gamma scintillation counter.

The

131
distribution of

I along thin layer chromatograms was determined by

counting each chromatogram divided into 5 m m sections in a well crystal
gamma scintillation counter.

131

Determinations of the iodine concentrations in

I solutions at

100 to 1000 m C i / m l were carried out by the bleaching of ferric thiocyanate colour.
3
The absolute activity of H in labelled compounds was determined
by liquid scintillation counting w i t h the addition of

3

H internal

standard for calibration. The relative radioactivity of animal organs
o
3
containing H was not m e a s u r e d . The relative concentrations of H
in tissue specimens were determined by dissolving 50-100 mg tissue samples
in Nuclear Chicago N . C . S . reagent then adding liquid scintillator and

counting in an Ansitron liquid scintillation spectrometer.
for quenching were made by the addition of 0.1|.lCi of

Corrections

3
H to each vial

3
and recounting.

The distribution of

H along thin layer chromatograms

was determined by liquid scintillation counting of the chromatogram
divided into 5 mm sections each of which was added to liquid scintillator in a counting vial.
3.
A.

PREPARATION OF QUINOLINE DERIVATIVES
Mononitroquinolines
(i)

5-Nitroquinoline
(a)

5-Nitroquinoline was prepared in

5 0 7 o

yield (together

with 7-nitroquinoline (c.f. (iii)) from 3-nitroaniline by the Skraup
reaction^^ m.p. 70° (lit.^^ 71°).

(Found: C, 61.8; H, 3.6; N, 16.0.

Calc. for C^H^N^O^: C, 62.0; H, 3.5; N, 16.1%).
(b)

5-Nitroquinoline, prepared in

nitration of q u i n o l i n e h a d

4 5 7 o

yield by the direct

m.p. 70-71° and was identical with the

above material.
(ii)

6-Nitroquinoline

6-Nitroquinoline was prepared in 547» yield from 4-nitroaniline by
the Skraup reaction^^'^^ m.p. 149° (lit.^^ 148-149°).

(Found: C, 61.9;

H, 3.6; N, 16.1. Gale, for C^H^N^O^: C, 62.0; H, 3.5; N, 16.1%).
(iii) 7-Nitroquinoline
7-Nitroquinoline was prepared in 107» yield [ together with
5-nitroquinoline (c.f. (i)a) ] from 3-nitroaniline by the Skraup
reaction^^ m.p. 134° (lit.^^ 136°).

(Found: C, 61.9; H, 3.5; N, 15.9.

Calc. for C^H^N.O.: C, 62.0; H, 3.5; N, 16.1%).
V o Z Z

B.

Monoaminoquinolines
(i)

4-Aininoquinoline

4-Aminoquinoline monohydrate was prepared in

637o

yield from

4-chloroquinoline (c.f. C (i)) by reaction with ammonia in boiling
phenol

73

m.p. 67-68° (lit.

Calc. for C^HgN^.

H^O:

5^

67°). (Found: C, 66.3; H, 6.0; N, 17.3.

C, 66.6; H, 6.2; N, 17.3%).

On drying

anhydrous 4-aminoquinoline of m.p. 152.5-153.5° (lit.^^ 154-155°)
was obtained.

(Found: C, 74.7; H, 5.6; N, 19.4.

Calc. for C^H^N,:
9 o 2

C, 75.0; H, 5.6; N, 19.4%). 5 8.40, 6.70 (2H, 2d, J 5.2 Hz; H2 and H3),
6.83 (2H, s; NH^).
(ii)

5-Aminoquinoline
(a)

5-Aminoquinoline was prepared in 95% yield from 5-

nitroquinoline (c.f. A (i)) by catalytic reduction in glacial acetic
acid solution with hydrogen at atmospheric pressure and 1.5 to 2% of
the 5-nitroquinoline weight of palladium at a concentration of 5% on
barium sulphate m.p.
H, 5.6; N, 19.1.

5

110-110.5° (lit.^^ 108-110°).

(Found: C, 75.3;

Calc. for C^H^N^: C, 75.0; H, 5.6; N, 19.4%).

8.82 (IH, 2d, J

4.1 Hz, J . , 1.7 Hz; H2), 7.40 (IH, 2d, J_ _4.1 HzJ^ ,

8.6 Hz; H3), 7.26 (IH, m; H4), 6.81 (IH, 2d, J, ^ 7.1 Hz, J^ ^ 1.7 Hz;
—O , /
—D , O
H6), 7.50 (IH, 2d, ¿^ ^ 7.1 Hz, J^ g 8.3 Hz; H7), 8.57 (IH, m; H8),
5.95 (2H, s; - NH^).
(b)

5-Aminoquinoline was prepared in 617o yield from

5-nitroquinoline by reduction with iron powder in the presence of
58
chloride ions
material.

o
m.p. 103-105 , undepressed on admixture with the above

(iii) 6-Aminoquinoline
6 - A m i n o q u i n o l i n e w a s p r e p a r e d in 917o y i e l d

(a)
6-nitroquinoline

( c . f . A ( i i ) ) by c a t a l y t i c r e d u c t i o n as for

5 - A m i n o q u i n o l i n e m . p . 1 1 3 - 1 1 4 . 5 ° ( l i t . ^ ^ ' ^ ^ 114°).

( F o u n d : C , 75.1;

H , 5.7; N , 1 9 . 2 . C a l c . for C ^ H g N ^ : C , 7 5 . 0 ; H , 5.6; N ,
(b)

from

19.4%).

6 - A m i n o q u i n o l i n e w a s p r e p a r e d in 567» y i e l d

from

6 - n i t r o q u i n o l i n e by r e d u c t i o n w i t h i r o n and a c e t i c a c i d ^ ^ ' ^ ^
and i d e n t i c a l w i t h the a b o v e
(c)

108-110

o

material.

6 - A m i n o q u i n o l i n e w a s p r e p a r e d in

yield

6 6 7 o

from

6 - n i t r o q u i n o l i n e by r e d u c t i o n w i t h s t a n n o u s c h l o r i d e in h y d r o c h l o r i c
a c i d ^ ^ ' ^ ^ m . p . 1 1 0 - 1 1 2 ° and i d e n t i c a l w i t h the above m a t e r i a l .
(iv)

7-Aminoquinoline

7 - A m i n o q u i n o l i n e d i h y d r a t e w a s p r e p a r e d in
7-nitroquinoline

8 8 7 o

yield

( c . f . A ( i i i ) ) by c a t a l y t i c r e d u c t i o n as for

5 - a m i n o q u i n o l i n e m . p . 7 1 . 5 - 7 2 . 5 ° ( l i t . ^ ^ ' ^ ^ 74-75.5°).
anhydrous 7-aminoquinoline was obtained m . p . 91-92
( F o u n d : C , 74.7; H , 5.8; N , 1 9 . 8 .
N ,

Hz,2

1 9 . 4 7 o ) .

8 . 6 9

( I H ,

2 d ,

J ^

3

4 . 3

o

On drying

(lit.

57 94
o
'
9 3 . 5 - 9 4 ).

C a l c . for C ^ H g N ^ : C , 75.0; H , 5.6;
H z

J ^ ^ ^

1 . 8

H z ;

H 2 ) ,

7 . 1 1

( I H ,

2 d ,

8 . 2 Hz; H 3 ) 8 . 0 5 ( I H , m ; H 4 ) , 7.73 ( I H , m ; H 5 ) , 7.20 (IH, 2 d , J ^ ^ ^
3,4
'

9.4 H z , ^
o
— o ,0
C.

from

2.5 Hz; H 6 ) 7.21 ( I H , m ; H 8 ) , 5.75 ( 2 H , s;NH ).
^

Monohalogenoquinolines
(i)

4-Chloroquinoline

4 - C h l o r o q u i n o l i n e w a s p r e p a r e d as an oil in
4-nitroquinoline-l-oxide

8 9 7 o

yield

( c . f . G (i)) by r e a c t i o n w i t h

t r i c h l o r i d e in c h l o r o f o r m . ^ ^

from

phosphorous

T h e crude p r o d u c t w a s n o t p u r i f i e d

but

was used directly in the preparation of 4-aminoquinoline.
(ii)

5-Iodoquinoline

5-Iodoquinoline was prepared in

yield from 5-aminoquinoline

8 9 7 o

f» B (ii)) by the Sandmeyer reaction, using 5-aininoquinoline which
had been further purified by a double precipitation of the hydrochloride
from ether.

The product was isolated by steam distillation m.p.

102-103° (lit.^^ 104-105°). (Found: C, 42.2; H, 2.4; N, 5.3.

Gale,

for C^H^IN: C, 42.4; H, 2.4; N, 5.5%).
(iii) 6-Iodoquinoline
(a)

6-Iodoquinoline was prepared in

2 7 7 o

yield from

6-aminoquinoline (c.f. B (iii)) by the Sandmeyer reaction as for
5-iodoquinoline m.p. 83-84° (lit.^^ 88°).
N,

5.5 .

;

Gale, for G^H^IN: G, 42.4; H, 2.4; N, 5.5%).
(b)

6-Iodoquinoline was prepared in

4-iodoaniline by the Skraup reaction
(iv)

(Found: C,42.3; H, 2.5

2 0 7 o

m.p. 86.5-88

yield from
(lit.

88 ).

7-Iodoquinoline

7-Iodoquinoline was prepared from

7-aminoquinoline (c.f. B (iv))

by the Sandmeyer reaction as for 5-iodoquinoline.
30
steam distillation was an oil (lit.

The free base from
o

b.p. 176-179 /lO mm) from which

the hydrochloride of 7-iodoquinoline was prepared m.p. 216-217°.
(Found: G, 37.1; H, 2.5; N, 4.7.

G^H^Gl IN requires: C, 37.1; H, 2.4;

N, 4.8%). 5 9.36 (IH, m; H2), 8.02 (IH, 2d,

5.1 Hz,

8.4

Hz; H3), 9.20 (IH, m; H4), 8.13-8.18 (2H, m; H5, H6), 8.88 (IH, m; H8).
D

Monohydrazinoquinolines
(i)

5-Hydrazinoquinolines

5-Hydrazinoquinoline was prepared from 5-aminoquinoline (cof» B(ii))

by diazotisation and reduction of the diazonium compound with stannous
chloride^^ and isolated in
247-248° (lit.^^ 247°).

877o

yield as the dihydrochloride m.p.

The free base, 5-hydrazinoquinoline, was

liberated by sodium hydroxide solution from the above hydrochloride
m.p. 152-153° (lit.^^ 150-151°).
Calc. for C^H^N :

C, 67.9;

(Found: C, 68.1;

H, 5.7;

N, 26.4%).

H, 5.8;

N, 26.1.

5 8.83 (IH, 2d, J. .
z, J

4.3 Hz, J^^^ 1.8 Hz; H2) 7.35 (IH, 2d, J^ 3 4.3 Hz, J^ ^ 8.6 Hz; H3),
7.30 (IH, m; H4), 7.09 (IH, 2d, J^ ^ 7.4 Hz, J^ ^ 1.7 Hz; H6), 7.60
(IH, 2d,

7.4 Hz, J^^g 8.4 Hz; H7) 8.59 (IH, m; H8), 7.67 (IH, s;

NH), 4.14 (2H, s; NH^).
E.

Quinoline-l-Oxide
Quinoline-l-Oxide was prepared in

907o

yield from quinoline by

oxidation with hydrogen peroxide in glacial acetic acid as described
O CT

by Ochiai

m.p. 58° (lit. 62°) (Found: C, 73.9;H, 5.1; N, 9.6. Calc.

for C^H^NO:
F.

C, 74.4; H, 4.9; N, 9.7%).

Monohalogenoquinoline-1-oxides
(i)

5-Iodoquinoline-l-oxide was prepared in

907o

yield from
35

5-iodoquinoline (c.f. C (ii)) as for quinoline-l-oxide above,
m.p. 159-161°.

(Found: C, 39.6;

C, 39.9; H, 2.2; N,

5.27o).

H, 2.2; N, 5.0.

C^H^ INO requires:

68.75 (IH, m; H2), 7.69 (IH, 2d, J^ 3 6.1

Hz, J3 ^ 9.1 Hz;

H3), 8.27 (IH, m;

J^ g 1.1 Hz; H6)

7.97 (IH, 2d, ^ ^ ^ 7.7 Hz, J^^g 8.9 Hz; H7), 8.94

(IH, m; H8).
G.

Mononitroquinoline-l-oxides

H4), 8.53 (IH, 2d, J^^^ 7.7 Hz,

(i)

4-Nitroquinoline-l-oxide

4-Nitroquinoline-l-oxide was prepared in

607o

yield by nitration
oc

of quinoline-l-oxide (c.f. E ) as described by Ochiai

m . p . 155-156°

(lit.^^ 153-154°).

Calc. for

(Found: C , 56.6; H , 3.2; N , 14.3.

S"6V3'

N , 14.7%). 6 8 . 7 5 , 8.36 (2H, 2d, J 7.0

Hz; H2 and H 3 ) .
(ii)

5-Nitroquinoline-l-oxide

5-Nitroquinoline-l-oxide was prepared in 74% yield from 5-nitroquinoline (c.f. A (i)) under the conditions given for the preparation
of quinoline-l-oxide^^ above,m.p. 136° (lit.^^ 155-157°).
C , 56.6; H , 3.2; N , 14.6.

(Found:

Calc. for C^H^N^O^: C , 56.8; H , 3.2;

N , 14.7%).
(iv)

7-Nitroquinoline-l-oxide

7-Nitroquinoline-l-oxide was prepared in 49% yield from 7-nitroquinoline (c.f. A (iii)) under the conditions given for the preparation
of quinoline-l-oxide^^ above, m . p . 178-179° (lit.^^ 174-175°).
C , 56.7; H , 3.3; N , 14.6.
N , 14.7%).

(Found:

Calc. for C^H^N^O^: C , 56.8; H , 3.2;

58.69 (IH, m; H2), 7.64 (IH, 2d, J

z, J

5.0 H z , J . . 8.5 Hz;
J, 4

H 3 ) , 8.04 (IH, m; H 4 ) , 8.33 (2H, m; H5 and H6), 9.15 (IH, m; H8).
H.

Dinitroquinoline-l-oxides
(i)

4,5-Dinitroquinoline-l-oxide

4,5-Dinitroquinoline-l-oxide was prepared in 647o yield by the
nitration of 5-nitroquinoline-l-oxide (c.f. G (ii)) under the conditions
35
for the preparation of 4-nitroquinoline-l-oxide

above (c.f. G (i))

and on recrystallisation from ethanol-dimethylformamide had m . p .

265-266° dec. (lit.^^ 260-262° dec.).
N, 17.8.

(Found: C, 45.7; H, 2.3;

Gale, for C^H^N^O^: C, 46.0; H, 2.2; N,

17.97o). 6 8.95,

8.48 (2H, 2d, J 6.9 Hz; H2 and H3), 9.00 (IH, 2d, ^

^ 8.7 Hz,

J^^g 1.4 Hz; H6), 8.19 (IH, 2d, J^ ^ 8.7 Hz, J^ ^ 7.9 Hz; H7),
8.79 (IH, m; H8).
(ii)

4,6-Dinitroquinoline-l-oxide

4.6-Dinitroquinoline-l-oxide was prepared in

827o yield

by

nitration of 6-nitroquinoline-l-oxide (c. f. G (iii)) under the
conditions for the preparation of 4,5-dinitroquinoline-l-oxide above,
OC
m.p. 224.5-225.5° dec. (lit.
N, 17.8.

218° dec.).

(Found: C, 45.7; H, 2.2;

Gale, for G^H^N^O^: G, 46.0; H, 2.2; N, 17.9%). 58.98,

8.61 (2H, 2d, J 6.9 Hz; H2 and H3), 9.65 (IH, 2d, —J
J. ,^/ 2.5 Hz, J^
—J ^
,o
0.8 Hz; H5).
(iii)

4,7-Dinitroquinoline-l-oxide

4.7-Dinitroquinoline-l-oxide was prepared in 467» yield by nitration
of 7-nitroquinoline-l-oxide (c. f. G (iv)) under the conditions for the
preparation of 4,5-dinitroquinoline-l-oxide above,m.p. 200-201° dec.
(Found: G, 45.9; H, 2.3; N, 17.6.

G^H^N^O^ requires: G, 46.0; H, 2.2;

N, 17.97o). 6 8.98, 8.61 (2H, 2d, J 7.0 Hz; H2 and H3), 8.99 (IH, 2d,
J^ ^ 9.5 Hz, J^ g 0.7 Hz; H5), 8.67 (IH, 2d, J^^^ 9.5 Hz, J^^g 2.5 Hz;
H7)^
1.

9.23 (IH, d, J^^g 2.5 Hz; H8).
Nitro-halogenoquinoline-l-oxide
(i)

4-Nitro-5-iodoquinoline-l-oxide

4-Nitro-5-iodoquinoline-l-oxide was prepared in

437o yield

from

5-iodoquinoline-l-oxide (c.f. F (i)) by nitration under the conditions

for the preparation of 4-nitro-quinoline-l-oxide above (c.f. G (i))
m.p. 234-237° dec.

(Found: C, 33.8; H, 1.5; N, 8.4.

C^H^IN^O^

requires: C, 34.2; H, 1.6; N, 8.9%). 5 8.60, 8.40 (2H, 2d, J 6.8 Hz;
H2 and H3), 8.10 (IH, 2d, ^ ^ ^ 7.2 Hz, J^ ^ 8.2 Hz; H7).
(ii)

4-Nitro-6-iodoquinoline-l-oxide

4-Nitro-6-iodoquinoline-1-oxide was prepared in

537o

yield from

6-iodoquinoline (c.f. C (iii)) which had been converted to the -1-oxide
but only isolated as a crude product on evaporation of the solvent, by
nitration under the conditions for the preparation of 4-nitroquinoline1-oxide (c.f. G (i)) above m.p. 157-161°.
J.

Amino-nitro-quinolines
(i)

4-Amino-5-nitroquinoline

4-Amino-5-nitroguinoline was prepared from 4-chloro-5-nitroquinoline
(c.f. L (i)) by reaction in refluxing phenol solution with dry ammonia
73
under the conditions described by Keneford et al.
or at

1 4 0 - 1 5 0 °

when a

757o

yield was obtained.

isolated as the monohydrate m.p.
N,

2 0 . 5 ,

.

7 3 - 7 4

CgH^N^O^.H^O requires: G,

5 2 . 2 ;

(Found: C,
H,

6 . 9 4

yield

4 . 4 ;

N,

5 2 . 2 ;

2 0 . 3 % ) .

H, 4.2;
On drying

m.p.121-122°.

C^H^N^O^ requires: C, 57.1; H, 3.7;

N ,

2 2 . 2 % ) .

^

^ 7.6 Hz, J^ g 2.1 Hz; H6), 7.64 (IH, t, J^^^ 7.6 Hz, J^^g 7.5 Hz;

5

8 . 5 0 ,

537o

This compound was

anhydrous 4-amino-5-nitroquinoline was obtained of
(Found: C, 57.3; H, 3.8; N, 22.0.

giving a

( 2 H ,

2 d ,

J

5 . 4

H z ;

H 2

a n d

H 3 ) ,

8 . 0 9

( I H ,

2 d ,

H7), 7.85 (IH, m; H8), 6.16 (2H, s; NH^).
(ii)

4-Amino-6-nitroquinoline

4-Amino-6-nitroquinoline was prepared in 83% yield from 4-chloro-

6-nitroquinoline (c.f. L (ii)) by reaction in refluxing phenol with
dry ammonia as described by Keneford et al,

7

m.p. 314-315° dec.

"7
(lit.

310-313°).

(Found: C, 56.8; H, 3.8; N, 21.9.

Calc. for

22.27o). (At 100 MHz) 68.35, 6.62
(2H, 2d, J 5.3 Hz; H2 and H3), 9.24 (IH, d, J

J, /

2.2 Hz, H5), 8.24

(IH, 2d, J^^^ 2.2 Hz, J^^g 9.1 Hz; H7), 7.81 (IH, m; H8), 7.37 (2H,s;
NH^).
(iii)

4-Amino-7-nitroquinoline

4-Amino-7-Nitroquinoline was prepared in 11% yield from 4-chloro7-nitroquinoline (c.f. L (iii)) by reaction in refluxing phenol with
73
dry ammonia under the conditions
(Found: C, 56.8; H, 3.7; N, 22.2.
N,

22.27o).

68.52,

used above

o
m.p. 300-301° dec.

C^H^N^O^ requires: C, 57.1; H, 3.7;

6 . 7 8 (2H, 2d, J 5.2 Hz; H2 and H 3 ) , 8 . 4 5

(IH,

d,

J^ ^ 9.4 Hz; H5), 8.09 (IH, 2d, J^ ^ 9.4 Hz, J^ g 2.4 Hz; H6), 8.58
(IH, d, ^ o 2.4 Hz; H8), 7.17 (2H, s; NH.).
•~o , o
L
K.

Diamino Quinolines
(i)

4,5-Diaminoquinoline
(a)

The attempted preparation of 4,5-diaminoquinoline

from 4-amino-5-nitroquinoline (c.f. J (i)) by reduction with stannous
chloride

73

gave only starting material.
(b)

The attempted preparation of 4,5-diaminoquinoline

from 4-amino-5-nitroquinoline in acetic acid as solvent by catalytic
reduction with hydrogen using a palladium on charcoal catalyst gave
an acetate salt which sintered at>100° and finally melted at 172-173°.
(ii)

4,6-Diaminoquinoline

4,6-Diaminoquinoline was prepared in 607» yield from 4-amino-6nitroquinoline (c.f. J (ii)) by reduction with stannous chloride as
described by Keneford at al.^^ m.p. 215-215.5° (lit.^^ 214°).
C, 67.7; H, 5.7; N, 26.1.

(Found:

Gale, for G^H^N^: G, 67.9; H, 5.7; N, 26.4%).

J, /

68.00, 6.38 (2H, 2d, J 5.0 Hz; H2 and H3), 6.92 (IH, 2d, J. ^ 2.0 Hz,
-5,8

^5 7

:i7 8

H7), 7.50

(IH, m; H8), 6.17 (2H, s; NH^), 5.08 (2H, s; NH^).
(iii)

4,7-Diaminoquinoline
(a)

4,7-Diaminoquinoline was prepared in 807» yield from

4-amino-7-nitroquinoline (c.f. J (iii)) by reduction with stannous
73
chloride as for 4,6-diaminoquinoline
H,

5.9;

6.20

N,

26.4.

C^H^N^ requires;

(2H, 2d, J 5.2 Hz; H2 and H3,

G,

o
m.p.

67.9;

7.79

211-213

.

(Found:

G,

5.7:

N,

26.47o).

6

H,

67.9;

8.02,

(IH, d, J J , D 9.5 Hz; H5), 6.85

(IH, 2d, J^ ^ 9.5 Hz,

g 2.3 Hz H6), 6.85 (IH, d, ¿^ ^ 2.3 Hz; H8),

6.40 (2H, s; NH^), 5.03

(2H, s; NH^).

(b)

The preparation of 4,7-diaminoquinoline from 4,7-

dinitroquinoline-l-oxide (c.f. H (iii)) was attempted by catalytic
reduction in glacial acetic acid containing a trace of hydrogen chloride
with hydrogen at atmospheric pressure and palladium on charcoal catalyst.
The rate of gas absorption was slow and after 5 hours reaction insufficient product was isolated for identification.
L.

Halogeno-nitroquinolines

(i)

4-Ghloro-5-nitroquinoline

4-Ghloro-5-nitroquinoline was prepared from
1-oxide

(c.f. H (i)) by reaction with phosphorus

4,5-dinitroquinolinetrichloride in

chloroform as described by Hamana^^ for the preparation of 4-chloroquinoline from 4-nitroquinoline-1-oxide.

The product was isolated

from the reaction mixture after excess reagent was hydrolysed with
water, the chloroform removed by distillation and the solution
neutralised to give a
o
152-154

7 0 7 o

yield of 4-chloro-5-nitroquinoline, m.p.

32
(lit.

150°).

(Found: C, 52.1; H, 2.5; N, 13.0.

for C^H^Cl N^O^: C, 51.8; H, 2.4; N, 13.4%).

Calc.

5(in CD CI3) 8.84,

7.60 (2H, 2d, J 4.7 Hz; H2 and H3), 7.72-7.82 (2H, m; H6 and H8),
8.30 (IH, m; H7).
(ii)

4-Chloro-6-nitroquinoline

4-Ghloro-6-nitroquinoline was prepared in ITL yield from 4,6dinitroquinoline-l-oxide (c.f. H (ii)) by reaction with phosphorus
trichloride in chloroform as used o for the3 ^preparation
of 4-chloro-5o
nitroquinoline above m.p, 144-145" (lit."-" 142.5'').
H, 2.5; N, 13.1.

(Found: C, 51.5;

Calc. for C^H^Cl N^O^: C, 51.8; H, 2.4; N, 13.1%).

6(in CDCl^) 8.92, 7.62 (2H, 2d, J 4.8 Hz; H2 and H3), 9.13 (IH, 2d,
J^ ,^/ 2.5 Hz, J.
Hz; H5), 8.49 (IH, 2d, J.
2.5 Hz, J^—/.,9.1
—J
,o o0.7
—J ^, /
o
Hz; H7), 8.20 —J
(IH,
m; H8).
(iii)

4-Chloro-7-nitroquinoline
(a)

4-Chloro-7-nitroquinoline was prepared in

8 5 7 o

yield

from 4,7-dinitroquinoline-l-oxide (c.f. H (iii)) by reaction with
phosphorus trichloride in chloroform as used in the preparation of
4-chloro-5-nitroquinoline above m.p. 171-173°.

(Found: C, 51.7;

H, 2.3; N, 13.3. C^H^CIN^O^ requires: C, 51.8; H, 2.4; N, 13.1%).
6 ( i n CD C l ^ ) 8 . 9 3 , 7.65

( 2 H , 2 d , J 4 . 7 H z ; H 2 and H 3 ) ,

8.34-8.39

(2H, m; H5 and H6), 8.96 (IH, m; H8).
(b)

4-Hydroxy-7-nitroquinoline was prepared in 547o yield

from 3-carboxy-4-hydroxy-7-nitroquinoline (c.f. P (i)) by decarboxy72
lation of the silver salt in Dowtherm A
56.6; H, 3.1; N, 14.6.

m.p. 317-320°.

C^H^N^O^ requires:

(Found: C,

G, 56.8; H, 3.2; N, 14.8%).

4-Chloro-7-nitroquinoline was prepared from this compound by reaction
with phosphorus oxychloride as described for 4-chloro-6-nitroquinoline.^^
The product isolated of m.p. 173-174° showed no depression of melting
point with and could not be separated by thin layer chromatography
from authentic material.
(iv)
4-Nitro-5-iodoquinoline
4-Nitro-5-iodoquinoline was prepared from 4-nitro-5-iodoquinoline1-oxide (c.f. I (i)) by reaction with phosphorus trichloride in
chloroform, as used to prepare 4-chloro-5-nitroquinoline above, of
m.p. 157-159°.

(Found: C, 35.9; H, 1.8; N, 8.9.

C, 36.0; H, 1.7; N, 9.3%).

C^H^IN^O^ requires:

58.93, 7.67 (2H, 2d, J 4.6 Hz; H2 and H3),

7.80-7.89 (2H, m; H6 and H8), 8.37 (IH, t, J, ^ 5.0 Hz, J^ ^ 5.0 Hz; H7).
—D , /
—/ , O
M.

Halogeno-Amino quinolines
(i)

4-Amino-6-iodoquinoline
(a)

4-Amino-6-iodoquinoline was prepared in

857o

yield from

4-chloro-6-iodoquinoline (c.f. N (i)) by reaction in refluxing phenol
solution with dry ammonia as used for the preparation of 4-amino-6nitroquinoline above m.p. 222.5-223.5°.
10.3.

(Found: G, 40.3; H, 2.7; N,

G^H^IN^ requires: G, 40.0, H, 2.6; N, 10.4%).

(2H, 2d, J 5.2 Hz, H2 and H3), 8.61 (IH, d, J^ g

1.8

68.37,

6.61

Hz; H5), 7.57

( I H , d , J^ g 8.9 Hz; H 7 ) , 7.88 (IH, m; H 8 ) , 6.87 (2H,s; N H ^ ) .
(b)
diaminoquincline

4-Ainino-6-iodoquinoline w a s prepared from 4,6(c.f. K (ii)) by the Sandmeyer r e a c t i o n on the

250 |iM scale w i t h r e a g e n t s at 0 . 0 5 M c o n c e n t r a t i o n .

The diamino-

q u i n o l i n e w a s d i a z o t i s e d w i t h an equimolar quantity of p o t a s s i u m
n i t r i t e after w h i c h an equimolar quantity of p o t a s s i u m i o d i d e , w a s
added and the p r o d u c t isolated through chloroform to give 4-amino-6i o d o q u i n o l i n e of m . p . 2 1 1 - 2 1 4 ° identical (mixed m . p . , t.l.c. and
infrared s p e c t r u m ) w i t h the above m a t e r i a l .
(ii)

4-Amino-7-iodoquinoline
(a)

4 - A m i n o - 7 - i o d o q u i n o l i n e was prepared in

from 4 - c h l o r o - 7 - i o d o q u i n o l i n e

yield

(c.f. N (ii)) by r e a c t i o n in refluxing

p h e n o l w i t h dry ammonia as used for the p r e p a r a t i o n of 4-amino-6n i t r o q u i n o l i n e above m . p . 197-198°.

(Found: C , 39.8; H , 2.6; N , 10.1

C . H ^ I N ^ r e q u i r e s : C , 40.0; H , 2.6; N , 10.47»). 6 8 . 3 0 , 6.58 (2H, 2d,
9 / L
J

5.2 Hz; H2 and H 3 ) , 7o97 (IH, d , J^ ^ 8.9 Hz; H 5 ) , 7o63 (IH, 2 d ,

J^ ^ 8.9 H z , J^ g 1.3 Hz; H 6 ) , 8.17 (IH, d ,

1.2 Hz; H 8 ) , 6.84

(2H, s; N H ^ ) .
(b)
diaminoquinoline

4 - A m i n o - 7 - i o d o q u i n o l i n e was prepared from 4,7(c.f. K (iii)) by the Sandmeyer reaction on the 250

jiM scale and as for the p r e p a r a t i o n of 4-amino-6-iodoquinoline

above.

The p r o d u c t had m . p . 1 8 8 - 1 9 3 ° and w a s identical (mixed m . p . , t.l.c.
and infrared s p e c t r u m ) w i t h the above m a t e r i a l .
(iii)

4-Chloro-5-Aminoquinoline

T h e r e d u c t i o n of the n i t r o group in 4 - c h l o r o - 5 - n i t r o q u i n o l i n e

f« L (i)) with hydrogen at atmospheric pressure was attempted in
ethanol solution using platinum oxide catalyst.

No product correspond-

ing to an aminochloroquinoline could be isolated from the reaction.
C O

The attempted reduction with iron in the presence of chloride ions
and iron and acetic acid^^'^^ also proved unsuccessful.
(iv)

4-Chloro-7-aminoquinoline

The attempted preparation of 4-chloro-7-aminoquinoline from
4-chloro-7-nitroquinoline by reduction of the nitro group with sodium
dithionate in 607o ethanol under reflux gave starting material.

Only

7-aminoquinoline was isolated from the attempted reduction with hydrogen
at atmospheric pressure using a palladium on charcoal catalyst and
acetic acid as solvent.
N.

Dihalogenoquinolines
(i)

4-Chloro-6-iodoquinoline

4-Chloro-6-iodoquinoline was prepared from 3-carboxy-4-hydroxy-6iodoquinoline (c.f. 0 (i)) by decarboxylation followed by reaction with
phosphorus oxychloride under the conditions described by Riegel et al^^
for the preparation of 4-chloroquinoline giving a steam volatile
product of m.p. 142-143°.

(Found: C, 37.3; H, 1.8; N, 4<.8. C^H^Cl IN

requires: C, 37.3; H, 1.7; N, 4.8%). 5 (in CD Cl^) 8.82, 7.63 (2H, 2d,
J 4.7 Hz; H2 and H3), 8.58 (IH, d, J^ g 1.8 Hz; H5), 7.81 (IH, d, J^^g
8.9 Hz; H7), 8.07 (IH, m; H8).
(ii)

4-Chloro-7-iodoquinoline

4-Chloro-7-iodoquinoline was prepared from 3-carboxy-4-hydroxy-7iodoquinoline (c.f. 0 (ii)) by decarboxylation then reaction with

phosphorus oxychloride as for the preparation of 4-chloro-6-iodoquinoline, giving a product of m.p. 100-101° (lit.^^^ 101-102°).
(Found: C, 37.7; H, 1.8; N, 4.8.

Calc. for C^H^CIIN: C, 37.3,

H, 1.7; N, 4.8%). 5 (in CD Cl^) 8.74, 6.58 (2H, 2d, J 4.7 Hz; H2 and
H3), 7.87-7.89 (2H, m; H5 and H6), 8.54 (IH, m; H8).
0.

Carboxy-Hydroxy-Halogenoquinolines
(i)

3-Carboxy-4-hydroxy-6-iodoquinoline

3-Carboxy-4-hydroxy-6-iodoquinoline

was prepared from ethyl

carbethoxy-p -(4-iodophenylamino)-aerylate (c.f. Q (ii)) by cyclisation
then hydrolysis of the ester (not isolated) under the conditions
43
described by Price and Roberts

for the preparation of 3-carboxy-4-

hydroxy-7-chloroquinoline giving a product of m.p. 297-298° dec.
(Found: C, 38.1; H, 1.9; N, 4.3.

C^^H^INO^ requires: C, 38.1; H, 1.9;

N, 4.5%).
(ii)

3-Carboxy-4-hydroxy-7-iodoquinoline

3-Carboxv-4-hvdroxy-7-iodoquinoline was prepared from ethyl
carbethoxy-p-(3-iodophenylamino)-acrylate

(c.f. Q (i)) by the reactions

and conditions for the above compound giving first a 797o yield of
o
25
3-carbethoxy-4-hydroxy-7-iodoquinoline m.p. 253-256

subl. (lit.

subl. 255°) which was hydrolysed in 98% yield to the acid m.p. 273-275°
(lit.^^ 278°).
P.
Carboxy-hydroxy-nitroquinolines
(i)

3-Carboxy-4-hydroxy-7-nitroquinoline

3-Carboxy-4-hydroxy-7-nitroquinoline was prepared from ethyl
carbethoxy-p-(3-nitrophenylamino)-acrylate

(c.f. Q (iii)) as for the

above compounds by cyclisation to 3-carbethoxy-4-hydroxy-7-nitroquinoline (not isolated) and hydrolysis of the ester to the acid m.p.
287° dec.

(Found: C, 51.2; H, 2.9; N, 11.8.

C^^H^N^O^ requires:

C, 51.3; H, 2.6; N, 11.9%).
Q.

Ethyl Carbethoxy(i)

-(monosubstituted pheny1amino)-aery1ates

Ethyl Carbethoxy- p-(3-iodophenylamino)-acrylate was

prepared from 3-iodoaniline by condensation with ethoxymethylene
^3
malonic ester

giving 89% yield of product m.p. 87.5-89® (lit.^^

88-89°).
(ii)

Ethyl carbethoxy-p-(4-iodophenylamino)-acrvlate, prepared

from 4-iodoaniline by condensation with ethoxymethy1enemaIonic ester
had m.p. 130-131°.

(Found: C, 43.3; H, 4.0; N, 3.6.

,

C^^H^INO^ requires:

C, 43.2; H, 4ol; N, 3.6%).
(iii) Ethyl carbethoxy-p-(3-nitrophenylamino)-acrvlate was
prepared from 3-nitroaniline by condensation with diethyl ethoxymethylene malonate

43

o
to give a product of m.p. 81-82 .

H, 5.3; N, 8.9.
R.

(Found: C, 54.7;

C, 54.5; H, 5.2; N, 9.1%).

Alkylamino-nitroquinolines
(i)

4-(3-dimethylaminopropylamino)-7-nitroquinoline was prepared

from 4-chloro-7-nitroquinoline (c.f. L (iii)) by the reaction under
reflux with an excess of 3-dimethylaminopropylamine as in the preparation
of the 7-iodo-compound

25

.

On dilution with water the product was

isolated as the monohydrate m.p. 88°.

(Found: C, 57.4; H, 6.7; N, 19.2.

C w H , ON,O^.H.O requires: C, 57.5; H, 6.9; N, 19.1%).
14 lo 4 2 Z
anhydrous base was obtained of m.p. 111.5-112°.

On drying the

(Found: C, 61.3;

H, 6.6; N, 20.2.

^^^H^gN^O^ requires: C, 61.2; H, 6.6; N, 20.4%).

68.54 (IH, m; H2), 6.66 (IH, d, J^ 3 5.0 Hz; H3), 8.39 8.07 (2H, m;
H5 and H6), 8.56 (IH, m; H8), 7.65 (IH, s; NH), 3.37 (2H, m or t after
D^O exchange; H 1^), 1.85 (2H, m; H 2^), 2.41 (2H, m; H 3 ^ , 2.20
(6H, s; NMe^).
S.

Alky1amino-aminoquinolines
(i)

4-(3-dimethylaminopropylamino)-7-aminoquinoline was prepared

from 4-(3-dimethylaminopropylamino)-7-nitroquinoline (c.f. above) by
73
reduction of the nitro group with stannous chloride
preparation of diaminoquinolines.

as for the

The product was isolated by

precipitation of tin sulphides from the double salt and crystallised
as the hydrochloride m.p. 211-213°.

(Found: C, 43.4; H, 6.3; N, 14.9.

requires: C, 43.2; H, 6.2; N, 14.57o). 68.21, 6.18
(2H, 2d, J 5.3 Hz; H2 and H3), 7.84, 6.85 (2H, m; H5 and H6i 6.94
(IH, m; H8), 6.78 (IH, s; NH), 5.37 (2H, s; NH^), 3.26 (2H, m; H 1^),
I.83 (2H, m; H 2^), 2.28 (2H, m; H 3^), 2.16 (6H, s; NMe^).
T

Alkylamino-halogenoquinolines
(i)

4-(3-dimethylaminopropylamino)-6-iodoquinoline was prepared

from 4-chloro-6-iodoquinoline (c.f. N (i)) by the reaction under reflux
in an excess of dimethylaminopropylamine and the product isolated as
described for the preparation of chloroquine^^^, m.p. 99-100°.

(Found:

C, 46.9; H, 4.9; N, 11.9 . C^^^H^glN^ requires; C, 47.3; H, 5.1; N, 11.8%).
5(in CD CI3) 8.48, 6.26 (2H, 2d, J 5.4 Hz; H2 and H3), 8.08 (IH, m; H5),
7.71-7.76 (2H, m; H7 and H8), 8.70 (IH, s; NH), 3.31 (2H, m or t after
D^O exchange; H 1^), 1.87 (2H, m; H 2^), 2.44 (2H, m; H 3^), 2.37

(6H, S; NMe^).
(ii)

4-(3-Dimethylaminopropylamino)-7-iodoquinoline
(a)

4-(3-Dimethylaminopropylamino)-7-iodoquinoline was

prepared from 4-chloro-7-iodoquinoline (c.f. N (ii)) by reaction with
dimethylaminopropylamine as carried out for the preparation of the
6-iodo-compound giving a 85% yield m.p. 100-101° (lit.^^ 101-103°).
(Found: C, 46.9; H, 5.5; N, 11.5.
H,

5 a ;

N,

11.87o).

5(in

CD

Cl^)

Calc. for
8.44,

6.25

(2H,

io

J

2d,

J

C, 47.3;
5.2

Hz;

H2

and

H3), 7.46 (IH, d, J. . 8.9 Hz; H5), 7.23 (IH, 2d, J^ ^ 8.9 Hz, J, ^
~J , O
—D , O
—D , O
2.1 Hz; H6), 7.90 (IH, d, ^

g 2.1 Hz; H8), 7.71 (IH, s; NH), 3.21

(2H, m or t after D^O exchange; H 1^) 1.77 (2H, m; H 2^), 2.36
(2H, m; H 3^) 2.20 (6H, s; NMe^).
(b)

4-(3-Dimethylaminopropylamino)-7-iodoquinoline was

prepared from 4-(3-dimethylaminopropylamino)-7-aminoquinoline (c.f.
S (i)) on the 250 |iM scale by the Sandmeyer reaction as for the
preparation of 4-amino-6-iodoquinoline (1. (i) (b) above.

The product

of m.p. 95° was identical (mixed m.p., t.l.c., infrared spectrum) with
the material above.
U.

Amino-hydrazinoquinolines
(i)

4-Amino-6-hydrazinoquinoline

4-Amino-6-hydrazinoquinoline was prepared from 4,6-diaminoquinoline
(c.f. K (ii)) by diazotisation of the 6-amino-group with an equimolar
quantity of nitrous acid then reduction of the diazonium compound with
74
stannous chloride as described by Hunsberger et al.

After

precipitation of tin sulphides from the double salt^^ 4-amino-6-

hydrazinoquinol ine was isolated as the dihydrochloride in.p. 311-312
(lit.

lO 2

302°).

(Found: C, 43.9; H, 4.9; N, 22.5.

Calc. for C^H.^N,.
9 10 4

2HC1: C, 43.7; H, 4.9; N, 22.7%).

LABELLING OF DERIVATIVES
A.

By
131
All labelling techniques involving

I were carried out in a

well ventilated cell constructed of 10 cm thick lead bricks.

Wherever

possible reaction vessels were used in lead shielded containers and
semi-remote handling techniques were employed.

The labelled compounds

prepared were not usually isolated as pure compounds but were formulated as solutions for administration to animals.
131
(i)

5-Iodoquinoline-

I was prepared from 5-aminoquinoline by

the Sandmeyer reaction on the 5 |iM scale (c. f. C (ii)).

0.1 ml of

0.05 M solution of 5-aminoquinoline in approximately 2 M hydrochloric
acid was injected through the rubber septum into a sealed 10 ml vial in
an ice bath.

0.1 ml. of 0.05 M potassium nitrite solution was added

and about 5 minutes later 0.1 ml of 50 mg/ml urea in about 2 M
131
hydrochloric acid.

25 mCi of

I in a solution

usually less than

0.2 ml and containing 5 |iM of potassium iodide was added.

After

standing 20 minutes and heating in a water bath to decompose the
diazonium compound, 0.2 ml of 407» w/v sodium hydroxide solution was
added to the cooled mixture and the contents of the vial were transferred to an all glass micro still.

With 0.1 ml of isotonic acetic acid

(0.145 M) in the receiver (which was vented to a trap of gas absorption

charcoal) cautious distillation was carried out until a few drops of
distillate containing suspended iodoquinoline were seen to drop into
the receiver.

The receiver contents in a 10 ml vial were diluted with

isotonic acetate buffer (pH 6.5) to give the concentration of radioactivity required and then the solution was sterilised by autoclaving
at 132*^ for 6 minutes.
(ii)

6-Iodoquinoline-

131

I was prepared from 6-aminoquinoline by

the Sandmeyer reaction as described for 5-iodoquinoline- 131I.
(iii)

7-Iodoquinoline-

131

I was prepared from 7-aminoquinoline

hydrochloride by the Sandmeyer reaction as described for 5-iodo. ,.
131
quinolineI.
(iv)

4-Amino-6-iodoquinoline-

131

I was prepared from 4,6-diamino-

quinoline by the Sandmeyer reaction on the 5|iM scale as described for
131
5-iodoquinoline-

I but the product was separated from the reaction

mixture by extraction into approximately 3 times the volume of chloroform.

The extract was washed twice with an equal volume of 0.9 mg/ml

sodium chloride solution and the product extracted back into 0.15 M
acetic acid solution.

This solution was diluted to the radioactive

concentration required with pH 6.5 isotonic acetate buffer, filtered
through an 0.22 [imillipore filter and sterilised by autoclaving at
132° for 6 minutes.
(v)

4-Amino-7-iodoquinoline-

131
I was prepared from 4,7-diamino-

quinoline by the Sandmeyer reaction as described for 4-amino-6-iodoquinoline.
(vi)

4-(3-Dimethylaminopropylamino)-7-iodoquinoline- 131I

(a)

4-(3-Dimethylaminopropylamino)-7-iodoquinoline-^^^I

was prepared from 4-(3-d
imethylaminopropylamino)7-aminoquinoline by the
Sandmeyer reaction
as described for 4-amino-6-iodoquinoline.
(b)
4-(3-Dimethylaniinopropylamino)-7-iodoquinoline-^^^I
was prepared from 4-(3-dimethylaminopropylamino)-7-iodoquinoline by
isotopic exchange.

16 25
'

8 mCi of

131

I were incorporated into the

quinoline when 100 mg of the quinoline were reacted for 2.5 hours with
1 o -1

25 mCi of a (1.7 mCi/|ig iodine) solution of

I.

Only 7 mCi were

incorporated into the quinoline when 100 mg of the quinoline were
reacted for the same period and the same
conditions with 150 mCi of
1 O 1
a 0.85 mCi/|ig of iodine solution of
I.
(c)

The preparation of 4-(3-dimethylaminopropylamino)-7-

131
iodoquinoline-

I from 4-(3-dimethylaminopropylamino)-7-iodoquinoline

by isotopic exchange was attempted by autoclaving a solution of 100 mg
of the quinoline in 5 ml of 0.01 N sulphuric acid at 120° for 1 hour
with

solution as sodium iodide.

Less than 5% of the

was

incorporated into the quinoline.
B.

By ^H
(i)

3
Quinoline-5- H was prepared from 5-hydrazinoquinoline by

reaction with an excess of tritiated water at 350 mCi/ml and copper
sulphate under the conditions described for the preparation of
• T
^ ^u
quinoline-jH.
(ii)

3
3
Quinoline-l-oxide-5- H was prepared from quinoline-5- H
35

by oxidation with hydrogen peroxide in acetic acid

o
at 55-60

for

20 hours and the crude product obtained by evaporation to dryness.

4-Nitroquinoline-l-oxide-5- H was prepared from the crude
3
oc
quinoline-l-oxide-5- H by nitration as described by Ochiai

for the

preparation of 4-nitroquinoline-l-oxide,and isolated as a crude
product m.p. 149-150° (lit.^^ 153-154°).
(iv)
4-Chloroquinoline-5- H was prepared from the crude 4-nitro
3
quinoline-l-oxide-5- H by reaction with phosphorus trichloride in
chloroform as described by Hamana^^ for the preparation of 4-chloroquinoline.

The crude product was isolated by the evaporation of

chloroform from the extracts.
(v)

4-Aminoquinoline-5- H was prepared from 4-chloroquinoline-

5-^H by reaction in refluxing phenol solution with dry ammonia^^ and
isolated by extraction into chloroform.

On gentle heating to

evaporate the solvent the anhydrous base was obtained m.p, 145-148°
53
(lit.

o
154-155 ) identical (mixed m.p», t.l.c., infrared spectrum)

with authentic material prepared above, and specific activity 2.7
mCi/mM.
(vi)

4-amino-6-hydrazinoquinoline was liberated from an aqueous

solution containing 0.1 mM of the dihydrochloride and extracted into
ether.

The combined extracts in a 10 ml vial were evaporated rapidly

to dryness then 30 mg of anhydrous copper sulphate with 0.5 ml of
60 mCi/ml tritiated water were autoclaved for 1 hour at 135° with the
contents of the vial.

The mixture was extracted with chloroform from

which negligible quantity of a radioactive product was recovered.
C.

Stability of the Labelled Material
(i)

4 - ( 3 - D i m e t h y l a m i n o p r o p y l a m i n o - 7 - i o d o q u i n o l i n e - 131 I.

(a)

The proportion of

I as free iodide was determined

by thin layer chromatography in a 10 |iCi/ml solution of the hydrochloride of 4-(3-dimethylaminopropylamino)-7-iodoquinoline-^^^I at a
specific activity of 28 mCi/mM then the solution was divided and one
part autoclaved at 120° for 30 minutes.

To the other part sodium

chloride was added to give a 9 mg/ml solution and it was also autoclaved,
131
(b)

The proportion of

I as free iodide ions was

determined for 4-(3-dimethylaminopropylamino)-7-iodoquinoline-^^^I
in 0.005 M sulphuric acid, at the concentration used above, before
and after autoclaving and after the addition of sodium chloride and
autoclaving as above.
131
(c)
The proportion of
I as free iodide was then
1 O1

determined for 4-(3-dimethylaminopropylamino)-7-iodoquinoline-

I

in 0.04 M citric acid solution at the concentration used above before
and after autoclaving.
(d)

20 ml of a solution of, 4-(3-dimethylaminopropylamino)

-7-iodoquinoline- 131 I in 0.04 M citric acid as used above was passed
3
through an anion exchange column 4 cm long containing 2.5 cm of Bio
Rad AGl X 8, 100-200 mesh, citrate form and the

131

I as free iodide ions

determined.
(e)

The radiochemical purity of

131

1 labelled 4-(3-

dimethylaminopropylamino)-7-iodoquinoline at a specific activity of
5 mCi/|iM in an autoclaved solution of acetate buffer was measured by
t.l.c. after preparation.
(ii)

Halogeno-4-aminoquinolines

107
131
The radiochemical purity of

I labelled 4-amino-6-iodo- and

4-amino-7-iodoquinoline in an autoclaved solution of acetate buffer
was determined by t.l.c. over a number of days after preparation.
The results are shown in Table 3,, (p.46).
(iii)

Monohalogenoquinolines131

The radiochemical purity of

I labelled 5-iodo,6-iodo and

7-iodo-quinolines was determined in solutions as in (ii) above.

The

results are shown in Table 3.
5.

DISTRIBUTION OF LABELLED MATERIAL IN EXPERIMENTAL ANIMALS.

A.

lodoquinolines(i)

I

5-Iodoquinoline-

131
I
131

0.2 ml of a 250 [iCi/ml sterile solution of 5-iodoquinoline-

I

at a specific activity of 5 mCi/|iM in acetate buffer solution was
administered to four hooded rats by intraperitoneal (i.p.) injection.
The rats were sacrificed consecutively at 24, 48, 72 and 96 hours after
injection. Each animal was dissected, skinned131
and the skin divided
into pigmented and non-pigmented areas. The
I distribution in the
organs, carcass and excreta were determined.
(ii)

6-Iodoquinoline-

131
I
131

0.2 ml of a 250 |iCi/ml sterile solution of 6-iodoquinolineat a specific activity of 5 mCi/[j^ in a acetate buffer solution was
administered to two hooded rats by i.p. injection.

One rat was

sacrificed at 72 hours and the other at 96 hours
after injection.
131
Each animal was dissected, skinned and the
I distribution in the

I

organs, carcass and excreta determined.
131
(iii)

7-lodoquinoline-

I

The 131 I distribution in organs, carcass and excreta was
131
determined for 7-iodoquinolineI administered to rats as described
for 6-iodoquinoline- 131 I above,
B.

4-AminO"iodoquinolines-

131

I
131

(i)

4-Amino-6-iodoquinoline(a)

I

0.2 ml of a 250 |iCi/ml sterile solution of 4-amino-6-

131
iodoquinoline-

I at a specific activity of 5 mCi/[JM in acetate buffer

and diluted to 0.5 ml with isotonic saline was administered by i.p.
injection to each of two hooded rats.

One rat was sacrificed at 72

and the other at 96 hours after injection.

Each animal was dissected

131
and the

I distribution determined in the organs and carcass.

The

131
I concentrations in tissue were determined in the animal sacrificed
96 hours after injection.
(b)

0.2 ml and 0.8 ml of the solution of 4-amino-6-iodo-

131
quinoline-

I used above were administered orally to two hooded rats.

The location of the radioactivity was assessed after 8, 24 and 96
hours from the distribution of gamma photons recorded by a Nuclear
Chicago Pho/Gamma HP Scintillation Camera using a pinhole collimator.
131
96 hours after administration the animals were sacrificed and the
distributions and concentrations in tissue were determined.
(ii)

4-Amino-7-iodoquinoline(a)

I

0.2 ml of a 250 [iCi/ml sterile solution of 4-amino-

7-iodoquinoline- 131 I at a specific activity of 5 mCi/[iM diluted to

I

0.5 ml with isotonic saline were administered by i.p. injection to
two hooded rats.

One animal was sacrificed at 72 and the other at

96 hours after injection and the 131 I distributions and concentrations
in tissue determined as for 4-amino-6-iodoquinoline- 131 I above.
(b)
iodoquinoline-

131

0.2 ml and 0.8 ml of the above solution of 4-amino-7I were administered orally to each of two rats and

gamma camera pictures and

131

I distributions and concentrations in

tissues were determined as for 4-amino-6-iodoquinoline- 131I.

6.

DISTRIBUTION OF LABELLED MATERIAL IN TUMOUR BEARING ANIMALS.
The animals used in these experiments were C-57 adult male mice

into which 10^ cells of a highly pigmented B16 melanoma had been
injected subcutaneously 10 days before the administration of the
labelled materials.
A.

4-Amino-iodoquinolines
(i)

4-Amino-6-iodoquinoline(a)

131
I

0.1 ml of a 100 |iCi/ml sterile solution in acetate

buffer of 4-amino-6-iodoquinoline-

131

I at a specific activity of

5 mCi/|iM was administered to three mice by i.p. injection.

96 hours

131
after injection the animals were sacrificed and the

I distribution

and concentrations in tissue were determined.
(b)
0.1 of the above solution was administered to two
mice orally and these were sacrificed 96 hours after administration
and the

1 31

I distributions and concentrations in tissue determined.

(ii)

4-Aiiiino-7-iodoquinoline(a)

131

I

0.1 ml of a 100 [iCi/ml sterile solution in acetate

buffer of 4-amino-7-iodoquinoline at a specific activity of 5 mCi/|iM
was administered to three mice by i.p. injection.

96 hours after

131
injection the animals were sacrificed and the

I distributions and

concentrations in tissue were determined.
(b)
0.1 ml of the above solution was administered orally
131
to two mice and the

I distributions and concentrations in tissue

determined in the animals which were sacrificed 96 hours after
administration.
B.

4-Alkyl-amino-iodoquinolines
131
(i)
4-(3-dimethylaminopropylamino)-7-iodoquinolineI
(a)

0.1 ml of a 100 |iCi/ml sterile solution in acetate
131

buffer of 4-(3-dimethylaminopropylamino)-7-iodoquinoline-

I at a

specific activity of 5 mCi/|iM was administered by i.p. injection to
five mice.

96 hours after injection each animal was sacrificed,
131

dissected and the

I distributions and concentrations in tissue

determined.
(b)

0.3 ml of the above solution was administered only

to one mouse which was sacrificed 96 hours after administration and
the

distribution was examined by the gamma camera.
131

was then dissected and the

I distribution and concentrations in

tissue determined.
C.
4-Aminoquinoline
(i)

The animal

3
4-Aminoquinoline-5- H

Ill

(a)

0.1 ml and a 0.05 ml volume of a 18 |iCi/ml sterile
3

solution in acetate buffer of 4-aminoquinoline-5- H at a specific
activity of 2.8 mCi/mM were administered by i.p. injection to two
mice. The animals 3were sacrificed after 96 hours and the relative
concentrations of H in tissues determined.
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